Certificate Course in Primary Care Neurology

? What Is Multiple Sclerosis?

Multiple sclerosis, or MS, is a chronic autoimmune demyelinating disorder that affects the central nervous system — specifically the brain, optic nerves, and spinal cord.

Let’s break it down: the body’s immune system — for unclear reasons — attacks the myelin sheath, which insulates nerve fibers. But it doesn’t stop there — this process also leads to inflammation, scarring (plaques), and eventually axonal damage. The result? Slow and disrupted nerve conduction, leading to a wide range of neurological symptoms that often come and go, or gradually worsen over time.

A hallmark feature of MS is that symptoms are disseminated in time and space — meaning they occur at different times and in different CNS locations.

?‍⚕️ Who Gets MS?

MS has a very specific demographic profile — most commonly:

• Young women

• Between the ages of 20 and 40

• Higher prevalence in individuals of Northern European descent

• Stronger association in temperate climates (latitude gradient)

• Genetic factors (e.g., HLA-DRB1) may increase susceptibility

? Clinical Presentation – Key Symptoms

MS presents with a wide range of neurologic signs, depending on which CNS area is affected. The exam question will usually give you a young woman with neurologic complaints that appear and resolve, and new ones arise later — classic for MS.

Let’s walk through the high-yield symptoms:

Optic Neuritis
This is often the first sign. It causes painful, monocular vision loss, especially with eye movement. The affected eye may also show an afferent pupillary defect (Marcus Gunn pupil).

Internuclear Ophthalmoplegia (INO)
Due to medial longitudinal fasciculus (MLF) lesion. On lateral gaze, the eye on one side fails to adduct, while the other eye has nystagmus. It’s a very specific finding in MS — especially if bilateral.

Limb Weakness and Spasticity
Usually due to spinal cord or corticospinal tract involvement.

Sensory Symptoms
Tingling, numbness, tightness, or a band-like sensation. Many patients describe paresthesias that come and go.

Lhermitte’s Sign
An electric shock-like sensation that runs down the spine when the patient flexes the neck — indicates cervical spinal cord demyelination.

Bladder Dysfunction
Patients may complain of urgency, frequency, or incontinence due to loss of descending control.

Fatigue
A prominent symptom, often disproportionate to physical findings, and worsened by heat (e.g., after a hot shower or exercise) — called Uhthoff’s phenomenon.

? Clinical Subtypes of MS

MS doesn’t behave the same in every patient. It’s classified into clinical types:

Relapsing-Remitting MS (RRMS)
The most common subtype, characterized by clearly defined relapses followed by full or partial recovery. Over time, most RRMS cases progress to a more chronic form.

Secondary Progressive MS (SPMS)
Initially starts as RRMS but later transitions into a gradual, irreversible neurologic decline, even without new attacks.

Primary Progressive MS (PPMS)
From the very beginning, patients experience steady worsening without relapses. More common in older onset, and harder to treat.

Progressive-Relapsing MS (PRMS)
The least common type — steady progression interspersed with acute relapses.

? How Do We Diagnose MS?

The diagnosis of MS is clinical, but confirmed with imaging and supportive tests.

MRI of Brain and Spinal Cord
This is the gold standard for confirming MS. On MRI:

• Look for hyperintense lesions (plaques) on T2-weighted and FLAIR sequences

• Classic locations:
  • Periventricular regions (especially “Dawson fingers”)
  • Juxtacortical
  • Infratentorial (e.g., brainstem, cerebellum)
  • Spinal cord

MRI confirms dissemination in space by showing lesions in different CNS areas.
Dissemination in time is demonstrated by:

• Simultaneous presence of enhancing (acute) and non-enhancing (old) lesions, or

• A new clinical episode separated from an old one by time.

Cerebrospinal Fluid (CSF) Analysis
Done via lumbar puncture. Typical findings include:

• Oligoclonal bands (seen in over 90% of MS cases)

• Mild lymphocytic pleocytosis

• Elevated IgG index

While CSF is not mandatory, it is supportive, especially when MRI findings are ambiguous.

? Management of MS

Management involves two main components: acute exacerbation treatment and disease-modifying therapy (DMT).

Acute Exacerbations
These are flares or relapses of symptoms.

• First-line treatment: High-dose IV corticosteroids, typically methylprednisolone

• If unresponsive: Consider plasma exchange (plasmapheresis)

Steroids work by reducing inflammation and speeding up recovery, but they do not alter disease progression.

? Disease-Modifying Therapies (DMTs)

These agents aim to reduce relapse frequency, delay disability, and slow progression.

Common DMTs include:

• Interferon-beta – reduces relapse rate and slows disability

• Glatiramer acetate – acts as a decoy for myelin basic protein

• Natalizumab – monoclonal antibody; effective but associated with PML (progressive multifocal leukoencephalopathy) risk

• Fingolimod – oral agent; requires cardiac monitoring due to risk of bradycardia

• Ocrelizumab – CD20 monoclonal antibody; effective in both RRMS and PPMS

Choice of therapy depends on disease severity, MRI burden, comorbidities, and risk profile.

⚙️ Symptomatic Management

Many MS symptoms persist or fluctuate even outside relapses. Targeted symptomatic treatment includes:

• Spasticity: Treated with baclofen or tizanidine

• Fatigue: May improve with amantadine

• Bladder dysfunction: Treated with anticholinergics like oxybutynin

• Neuropathic pain: Managed with gabapentin or pregabalin

• Depression: Common and should be screened and treated with SSRIs

? Key Exam Pearls for USMLE Step 2 CK

• Young woman with episodic neurologic complaints = think MS

• Optic neuritis, INO, and Lhermitte's sign are classic clues

• Uhthoff's phenomenon is heat-induced worsening

• MRI with periventricular plaques is diagnostic

• Oligoclonal bands in CSF = supportive evidence

• High-dose IV steroids treat acute relapses; DMTs prevent future ones

• Always monitor for natalizumab-associated PML

? Final Clinical Insights

Multiple sclerosis is a disease that unfolds slowly but leaves lasting impact. Diagnosing it early — based on pattern recognition of symptoms, knowing where lesions are likely to appear, and how to interpret the MRI — can make a massive difference in quality of life.

While there is no cure, modern therapies can dramatically reduce relapse rates and disability progression.

So remember, in exams and real life — if you’re given a young woman with visual, motor, or sensory complaints that come and go, and MRI shows periventricular lesions, your reflex answer should be: Multiple Sclerosis.

? Alzheimer’s Disease

? Introduction: What Is Alzheimer’s Disease?

Alzheimer’s disease — or simply AD — is the most common cause of dementia in older adults. It is a progressive neurodegenerative disorder, meaning the brain slowly and irreversibly declines in function over time. The hallmark feature? Memory loss — especially short-term memory, which is usually the first and most prominent symptom.

But AD isn’t just about forgetting things. It eventually affects language, executive function, orientation, judgment, personality, and the person’s ability to perform even the simplest daily tasks.

On USMLE Step 2 CK, you’ll often see a vignette involving an elderly individual who gets lost in familiar surroundings, has word-finding difficulty, or repeats questions — all pointing toward the early cognitive decline seen in Alzheimer’s.

? Pathophysiology: What Happens in the Brain?

Alzheimer’s disease involves two key microscopic abnormalities:

• Beta-amyloid plaques
  These are extracellular protein deposits that disrupt synaptic transmission and trigger inflammation.

• Neurofibrillary tangles
  Made of hyperphosphorylated tau protein, these develop inside neurons and impair the cell’s ability to transport nutrients and signals.

Together, these changes lead to neuronal death, synaptic loss, and brain atrophy, especially in the temporal and parietal lobes.

The hippocampus, responsible for forming new memories, is one of the earliest and most severely affected regions.

? Who Gets Alzheimer’s Disease?

Let’s talk about risk factors. The most significant ones include:

• Advanced age – by far the strongest risk factor

• Family history of dementia

• Female gender

• APOE ε4 allele – a known genetic risk factor

• Vascular risk factors – such as hypertension, diabetes, and hyperlipidemia

Early-onset familial forms are rare but do exist, caused by mutations in:

• APP (amyloid precursor protein) gene

• Presenilin-1 (PSEN1)

• Presenilin-2 (PSEN2)

These forms often present before age 60 and are more aggressive.

But remember — the vast majority of cases are sporadic, occurring without any known genetic mutation.

? Clinical Presentation: How Does It Start?

Alzheimer’s disease usually has an insidious onset — the changes are subtle at first and progress slowly over years.

Early-stage symptoms:

• Short-term memory loss — forgetting names, misplacing items, repeating questions

• Word-finding difficulty — using vague terms like “thing” or “stuff”

• Getting lost in familiar environments

• Difficulty with complex tasks — like managing finances or cooking

Progressive symptoms:

• Impaired judgment and reasoning

• Personality changes — such as apathy, irritability, or social withdrawal

• Disorientation — in time, place, and later, person

• Difficulty with daily living — bathing, dressing, feeding

Late-stage symptoms:

• Profound memory loss

• Mutism, immobility

• Incontinence

• Complete dependency on caregivers

Behavioral disturbances such as agitation, hallucinations, or wandering may also emerge and are often the most distressing for caregivers.

? Diagnosis: How Do We Confirm It?

There is no single test that definitively diagnoses Alzheimer’s disease. It’s a clinical diagnosis, based on:

History and Cognitive Testing
Use tools like:

• Mini-Mental State Examination (MMSE)

• Montreal Cognitive Assessment (MoCA)

These assess memory, attention, language, orientation, and visuospatial ability.

Neuroimaging (CT or MRI)
Primarily done to:

• Rule out reversible causes of dementia (like subdural hematoma, brain tumor, or normal pressure hydrocephalus)

• May show cortical atrophy, especially of the medial temporal lobe and hippocampus

Biomarkers
CSF analysis (in research or specialized centers) may show:

• Decreased beta-amyloid-42

• Increased total tau and phosphorylated tau

But remember — these are not necessary for clinical diagnosis.

? Management: How Do We Treat Alzheimer’s?

Unfortunately, Alzheimer’s disease is progressive and incurable, but treatment focuses on:

• Slowing progression

• Improving symptoms

• Supporting the patient and caregivers

Pharmacologic therapy:

1. Cholinesterase inhibitors – used in mild to moderate AD
   These include:
   • Donepezil
   • Rivastigmine
   • Galantamine
   They improve acetylcholine levels and offer modest cognitive benefit.

2. Memantine – an NMDA receptor antagonist used in moderate to severe AD
   It may help with cognition, behavior, and ADLs (activities of daily living).

Be realistic with patients and families: These medications do not reverse disease, but they may delay progression or preserve function for longer.

⚙️ Non-Pharmacologic & Supportive Care

This is just as important — if not more — than medications:

• Structured daily routines reduce confusion and anxiety

• Cognitive stimulation therapy can help preserve function

• Environmental modifications (like labels and calendars) improve safety

• Caregiver education and support groups reduce burnout

• Legal planning – discuss advance directives and durable power of attorney early in the disease

? Managing Associated Symptoms

Alzheimer’s doesn’t just affect memory — other symptoms can complicate care:

Depression
Very common. Use SSRIs like sertraline or citalopram cautiously.

Sleep disturbances
Non-drug strategies first (light exposure, consistent bedtime). Avoid benzodiazepines.

Agitation or psychosis
Avoid antipsychotics unless absolutely necessary — they carry increased mortality risk in dementia patients.

Incontinence and wandering
Behavioral strategies, supervision, and sometimes medications may be needed, but with caution.

? High-Yield points:

• Think Alzheimer’s when you see a gradual decline in memory and function in an elderly patient

• Early signs = short-term memory loss and word-finding difficulty

• CT/MRI may show hippocampal and temporal lobe atrophy

• First-line treatment = cholinesterase inhibitors

• Add memantine for moderate to severe stages

• Don’t forget non-pharmacologic interventions and caregiver support

? Final Thoughts

Alzheimer’s disease is a slowly unfolding tragedy, affecting not just the patient but the entire family. While we don’t yet have a cure, we have tools to diagnose early, preserve function, and support quality of life.

So when you're presented with that classic board vignette — an elderly woman who’s forgetting appointments, getting lost in the neighborhood, or struggling with word retrieval — your brain should immediately say: this could be Alzheimer’s disease.

⚡ Guillain-Barré Syndrome (GBS)

? What Is GBS?

Guillain-Barré Syndrome, or GBS, is an acute immune-mediated polyneuropathy that causes a rapidly progressive, symmetrical weakness, typically starting in the legs and ascending upward.

Now here’s the key: it’s not a primary muscle problem. The immune system — often triggered by a recent infection — mistakenly attacks the myelin sheath or axons of peripheral nerves, especially the motor fibers. The result is flaccid paralysis with diminished reflexes and potentially life-threatening respiratory failure.

This is a neurological emergency and a high-yield USMLE Step 2 CK topic, especially in questions involving post-infectious weakness.

? What Triggers GBS?

GBS is often preceded by a recent infection, typically 1 to 3 weeks prior. This is classic for board questions.

Common antecedent triggers include:

• Campylobacter jejuni – the most common trigger

• Upper respiratory tract infections

• Influenza virus

• Cytomegalovirus (CMV)

• Epstein-Barr virus (EBV)

• SARS-CoV-2 (COVID-19)

• Vaccinations – including influenza and rarely other immunizations

The immune response generated by these infections cross-reacts with peripheral nerve components (molecular mimicry), damaging the myelin or axonal structures.

? Pathophysiology

GBS involves immune-mediated damage to the peripheral nervous system.

Two major forms:

• Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) – most common in Western countries
  → Involves demyelination of peripheral nerves.

• Acute Motor Axonal Neuropathy (AMAN) – more common in Asia and Central America
  → Involves direct axonal damage.

The immune system generates antibodies against gangliosides on nerve membranes (e.g., anti-GM1), leading to either:

• Demyelination → slowed conduction

• Axonal degeneration → impaired nerve transmission

?‍⚕️ Clinical Presentation

The classic GBS presentation starts subtly, but progresses rapidly:

• Symmetrical weakness, usually begins in the lower limbs and ascends upward

• Areflexia – deep tendon reflexes are absent or diminished

• Paresthesias – tingling in the hands and feet

• Autonomic instability – including:

  • Tachycardia

  • Labile blood pressure

  • Urinary retention

  • Ileus

• Facial weakness – especially bilateral facial palsy (cranial nerve involvement)

• Respiratory distress – due to diaphragmatic and intercostal weakness

• Preserved mental status – cognitive function is normal

The most feared complication is respiratory failure, which may occur suddenly — that’s why early recognition and monitoring are critical.

? Diagnosis

GBS is primarily a clinical diagnosis, but investigations are done to support and confirm the findings.

Lumbar puncture (CSF analysis):

• Classically shows albuminocytologic dissociation:

  • High protein (>45 mg/dL)

  • Normal WBC count

This reflects inflammation with increased permeability of the blood-nerve barrier, without infection.

Nerve conduction studies (NCS) and electromyography (EMG):

• Confirm the diagnosis

• Show slowed conduction velocity or conduction block in demyelinating forms

• May show reduced amplitude in axonal variants

Pulmonary function testing:

• Serial monitoring of forced vital capacity (FVC) is essential

• FVC <20 mL/kg or a rapid decline indicates need for intubation and mechanical ventilation

? Management Approach

GBS requires prompt hospitalization, even in mild cases, because deterioration can be rapid and unpredictable.

Supportive care:

• Monitor respiratory function closely — serial FVC is your best friend

• Monitor autonomic signs — treat hypertension or bradycardia as needed

• Prevent complications:

  • DVT prophylaxis

  • Pressure sore prevention

  • Nutritional support

Specific therapies:

There are two equally effective first-line options:

1. IV Immunoglobulin (IVIG)

   • Given over 5 days

   • Works by neutralizing harmful antibodies and modulating the immune system

2. Plasmapheresis (Plasma exchange)

   • Removes circulating autoantibodies directly

   • Typically done in 4–6 sessions

Important: Do not give both IVIG and plasmapheresis together — they are not additive.

What does not work?

• Corticosteroids are not effective in GBS — and may even delay recovery

• This is a common USMLE trap

? Recovery and Prognosis

• Most patients begin to improve within weeks

• Recovery may take months to a year

• Around 80–90% recover fully, but some have:

  • Residual weakness

  • Fatigue

  • Neuropathic pain

Poor prognostic factors:

• Advanced age

• Rapid onset of weakness

• Need for mechanical ventilation

• Axonal subtype (AMAN)

• Severe autonomic instability

Rehabilitation plays a crucial role in maximizing functional recovery.

? Pearls:

• Young adult with ascending symmetric weakness + areflexia = think GBS

• Look for preceding diarrhea (Campylobacter) or respiratory illness

• CSF shows high protein with normal WBCs (albuminocytologic dissociation)

• Treatment = IVIG or plasmapheresis

• Corticosteroids? No!

• Monitor FVC closely — a drop may require mechanical ventilation

? Final Thoughts

Guillain-Barré Syndrome is a neurologic emergency, not a slow-onset neuropathy. It demands early recognition, close monitoring, and prompt immunotherapy.

On Step 2 CK, don’t be distracted by the infection history — focus on the clinical pattern:

• Ascending weakness

• Areflexia

• Recent infection

• Risk of respiratory failure

If you catch GBS early, you don’t just answer the question right — you prevent paralysis, and possibly save a life.

? Motor Neuron Disease (MND)

? What Is Motor Neuron Disease?

Motor Neuron Disease (MND) refers to a group of progressive neurodegenerative disorders that selectively affect motor neurons — the cells responsible for voluntary movement.

What’s unique? These disorders spare sensory pathways — so while patients experience paralysis and weakness, they continue to feel touch, pain, and temperature.

Among all subtypes of MND, the most high-yield and clinically relevant is Amyotrophic Lateral Sclerosis (ALS) — frequently tested on USMLE Step 2 CK.

? ALS: The Prototype of MND

ALS involves degeneration of both upper motor neurons (UMNs) in the corticospinal tract, and lower motor neurons (LMNs) in the anterior horn of the spinal cord.

Let’s define what that means:

• UMN degeneration causes:
  • Spasticity
  • Hyperreflexia
  • Clonus
  • Positive Babinski sign

• LMN degeneration causes:
  • Muscle atrophy
  • Fasciculations (muscle twitching)
  • Flaccid weakness
  • Hyporeflexia

This combined UMN + LMN picture is the classic hallmark of ALS — and helps distinguish it from many mimics.

Importantly, ALS spares:

• Sensation

• Cognitive function (except in rare cases with frontotemporal dementia)

• Bowel and bladder control

? Epidemiology & Genetics

ALS typically presents between the ages of 40 and 70. Most cases are sporadic, but about 10% are familial.

Among familial cases, a notable genetic mutation involves:

• SOD1 (superoxide dismutase 1) — seen in autosomal dominant forms

• Others include C9orf72 expansion (which can be associated with frontotemporal dementia)

? Clinical Presentation

ALS begins insidiously and progresses relentlessly. Symptoms depend on which motor neurons are affected first — limb onset vs. bulbar onset.

Limb-onset ALS:

• Asymmetric weakness, often in one arm or leg

• Patients may complain of:
  • Dropping objects
  • Tripping
  • Weak grip
  • Muscle cramps
  • Fasciculations in the limb

You’ll find:

• UMN signs: spasticity, brisk reflexes

• LMN signs: muscle wasting, fasciculations

Bulbar-onset ALS:

• Presents with speech and swallowing difficulties

• Dysarthria, dysphagia, nasal speech

• Tongue atrophy and fasciculations are classic

Eventually, ALS spreads to involve both upper and lower limbs, bulbar muscles, and respiratory muscles.

Respiratory involvement:

• Patients may complain of dyspnea, orthopnea, or morning headaches due to nocturnal hypoventilation

• Respiratory failure is the leading cause of death

Mental status is usually intact, though a subset may develop frontotemporal dementia (especially with C9orf72 mutation).

? Diagnostic Evaluation

ALS is a clinical diagnosis, based on the presence of both UMN and LMN signs in multiple body regions, with progressive worsening over time.

There is no single definitive test — instead, it’s a diagnosis of inclusion and exclusion.

Key investigations:

• Electromyography (EMG)
  Reveals widespread denervation and reinnervation – classic features include fibrillation potentials and positive sharp waves.

• Nerve conduction studies (NCS)
  Help rule out demyelinating neuropathies. In ALS, motor conduction may be abnormal, but sensory conduction is preserved.

• MRI of brain and spinal cord
  Used to exclude structural lesions like cervical cord compression, MS, or syringomyelia

• Serologic tests may be done to exclude mimics such as:

  • Multifocal motor neuropathy

  • HIV, Lyme disease

  • Paraneoplastic syndromes

? Important Differentiating Points

ALS vs. Peripheral Neuropathies:

• ALS has normal sensory function

• Peripheral neuropathies usually involve sensory loss and glove-stocking distribution

ALS vs. Myasthenia Gravis:

• MG affects neuromuscular junction, leading to fatigable weakness

• ALS shows both spastic and flaccid features, and progresses without fluctuation

? Management of ALS

While there is no cure, treatment focuses on:

• Slowing progression

• Managing symptoms

• Preserving quality of life

Disease-modifying agents:

1. Riluzole

   • Inhibits glutamate toxicity

   • Shown to modestly prolong survival (~2–3 months)

   • Monitor liver enzymes during therapy

2. Edaravone

   • A free radical scavenger

   • May help slow functional decline in early-stage ALS

   • Administered IV

These drugs do not stop the disease, but they delay progression.

? Multidisciplinary Supportive Care

Management involves a team approach — including neurology, physical therapy, palliative care, and respiratory support.

Key supportive strategies:

• Respiratory support
  • Use non-invasive ventilation (BiPAP) for hypoventilation
  • Consider tracheostomy in select cases

• Speech therapy
  • Helps with communication
  • Augmentative devices for advanced cases

• Nutritional support
  • PEG (feeding tube) may be needed due to dysphagia
  • Prevents aspiration and maintains weight

• Physical therapy
  • Maintains function and reduces contractures

• Palliative care
  • Focus on symptom control
  • Psychological and family support

? Prognosis

ALS is relentlessly progressive.

• Most patients die from respiratory failure within 3 to 5 years of diagnosis

• Bulbar-onset ALS typically progresses faster

• Limb-onset ALS may have a slightly longer course

However, some patients — like physicist Stephen Hawking — may survive for decades with slow progression.

?  High-Yield Summary

• Think ALS in a patient with progressive asymmetric weakness, fasciculations, spasticity, and no sensory loss

• Look for mixed UMN and LMN signs in multiple body regions

• Bulbar involvement = speech and swallowing problems

• EMG confirms denervation + reinnervation

• Riluzole and edaravone may slow progression, but don’t cure

• Death is usually due to respiratory failure

• Sensory and bladder function are preserved.

? Introduction: What Are Prion Diseases?

Prion diseases are a rare but fatal group of neurodegenerative disorders caused by an unusual mechanism: infectious protein misfolding.

Unlike bacteria or viruses, the causative agent is a protein — called a prion — which is an abnormally folded version of a normal host protein.

Let’s clarify the terminology:

• PrP^C: normal cellular prion protein

• PrP^Sc: misfolded, disease-causing isoform ("Sc" = scrapie, the prototypical animal prion disease)

The misfolded prion induces normal proteins to misfold, creating a chain reaction that leads to:

• Neuronal cell death

• Spongiform degeneration (giving the brain a sponge-like appearance)

• Astrocytosis, without any inflammation

This process is unique, progressive, untreatable, and always fatal — making it a key high-yield topic for USMLE Step 2 CK.

? Types of Prion Diseases

There are several prion diseases, but the most commonly tested and clinically encountered is Creutzfeldt-Jakob Disease (CJD).

Forms of CJD:

• Sporadic CJD (sCJD) – most common (~85% of cases)

• Familial CJD – due to inherited mutations in the prion protein gene (PRNP)

• Iatrogenic CJD – transmitted via contaminated surgical instruments, corneal transplants, or cadaveric growth hormone

• Variant CJD (vCJD) – linked to consumption of contaminated beef (bovine spongiform encephalopathy, aka "mad cow disease")

Other prion diseases:

• Gerstmann-Sträussler-Scheinker syndrome (GSS) – inherited, slower onset

• Fatal familial insomnia (FFI) – severe sleep disturbance progressing to death

• Kuru – historically seen in Papua New Guinea due to ritual cannibalism

?‍⚕️ Clinical Presentation: Creutzfeldt-Jakob Disease (CJD)

CJD is most classically tested and recognized for rapidly progressive dementia, typically evolving over weeks to months.

Let’s outline the major clinical features:

• Dementia: rapid decline in memory, attention, and executive function

• Myoclonus: especially startle-induced jerks — this is a key distinguishing feature

• Ataxia: cerebellar involvement causing unsteady gait or dysmetria

• Visual disturbances: blurred vision, diplopia, cortical blindness

• Pyramidal and extrapyramidal signs: rigidity, tremors, bradykinesia

• Akinetic mutism: late-stage patients become mute, unresponsive

• Coma and death: most die within 6–12 months

Variant CJD (vCJD):

• Affects younger patients (median age ~29)

• Starts with psychiatric symptoms: anxiety, depression, apathy

• Progresses to neurological decline over months

• Typically associated with bovine-derived food exposure

? Diagnosis of CJD

Diagnosis is clinical, but several supportive tests increase confidence.

EEG (Electroencephalogram):

• Periodic sharp wave complexes

• High specificity for sporadic CJD

• May be absent early, but becomes more apparent over time

MRI Brain:

• Best modality is Diffusion-Weighted Imaging (DWI)

• Classic findings:

  • Hyperintensity in basal ganglia (caudate and putamen)

  • Cortical ribboning – hyperintensities in the cerebral cortex

MRI is especially useful because it is noninvasive and highly sensitive

CSF Analysis:

• No specific test, but supportive findings include:

  • Elevated 14-3-3 protein

  • Elevated tau protein

  • RT-QuIC (real-time quaking-induced conversion): newer, more specific test used in some centers

Brain biopsy:

• Definitive diagnosis, but rarely performed due to:

  • Invasiveness

  • Infectious risk

  • High diagnostic yield from non-invasive tests

Histology shows:

• Spongiform changes (vacuoles in neuropil)

• Neuronal loss

• Gliosis

• Absence of inflammation

? Infectivity and Precautions

Prion proteins are extremely resistant to standard sterilization. That includes:

• Autoclaving

• Formaldehyde

• UV radiation

Special decontamination protocols must be followed when handling instruments exposed to prions.

Healthcare providers must be aware of this, especially in neurosurgery and pathology settings.

? Management and Prognosis

Sadly, there is no cure for prion diseases. The disease is universally fatal.

Management is supportive:

• Palliative care – for comfort, dignity, and family counseling

• Seizure control, if needed

• Nutritional support, if safe

• Hospice referral is usually appropriate once diagnosis is clear

Survival:

• Most patients with sporadic CJD die within 6 to 12 months

• Variant CJD may have a slightly longer course, but is still fatal

? Key Pearls:

• Think CJD in a patient with rapidly progressive dementia + myoclonus

• Startle-induced jerks are a red flag

• MRI shows basal ganglia hyperintensity and cortical ribboning

• CSF may have 14-3-3 protein, but diagnosis is still clinical

• EEG with periodic sharp waves is classic but not always present

• No treatment, only supportive care

• Take extra precautions with surgical instruments due to prion resistance

? Final Thoughts

Prion diseases are unique — not because of how common they are, but because of how terrifyingly rapid and untreatable they are.

They violate our usual approach to dementia, which tends to be slow and subtle. Instead, prion disease strips the brain of function at shocking speed, leaving patients profoundly debilitated in a matter of months.

As a clinician — and especially as someone preparing for exams — the key is to recognize the pattern:

• Rapid dementia

• Myoclonus

• Ataxia

• Abnormal MRI and EEG

• Absence of inflammation

• And sadly… no cure.

? Introduction: What Is Duchenne Muscular Dystrophy?

Duchenne Muscular Dystrophy (DMD) is one of the most severe and common childhood-onset muscular dystrophies. It’s a genetic disorder that leads to progressive muscle degeneration and weakness, and is a must-know condition for any Step 2 CK or pediatric board exam.

Let’s start with the cause.

DMD is due to a mutation in the dystrophin gene, located on the X chromosome — which means it follows an X-linked recessive inheritance pattern. That’s why it affects boys almost exclusively, while female carriers are usually asymptomatic.

The gene involved, DMD, is one of the largest human genes, which unfortunately makes it prone to mutations. These mutations typically result in complete absence of a key structural protein — dystrophin.

?️ What Does Dystrophin Do?

Dystrophin is a critical cytoskeletal protein that anchors the actin filaments inside muscle cells to the extracellular matrix via the dystrophin-glycoprotein complex.

In simple terms: dystrophin acts like a shock absorber during muscle contraction. Without it, muscle fibers are mechanically fragile and easily damaged.

The absence of dystrophin leads to:

• Membrane instability

• Muscle cell death

• Replacement of muscle tissue with fat and fibrous tissue

• Progressive muscle weakness

This degeneration starts in skeletal muscles, but eventually involves cardiac and respiratory muscles, and even affects the brain.

? Clinical Presentation: When and How Does DMD Appear?

The classic age of onset is between 2 to 5 years old. Children may appear normal at birth but begin to show signs of muscle weakness as they grow.

Early signs:

• Delayed motor milestones (e.g., walking late)

• Frequent falls

• Waddling gait

• Difficulty climbing stairs

• Trouble getting up from the floor

The hallmark sign is a positive Gowers’ sign — the child uses his hands to “climb up” his own thighs to rise from the floor. This occurs due to proximal muscle weakness, especially in the pelvic girdle.

Other features:

• Pseudohypertrophy of the calves
  The calf muscles appear large, but they’re actually filled with fat and connective tissue, not functioning muscle.

• Lumbar lordosis

• Contractures, especially at the ankles and hips

• Progressive scoliosis as back muscles weaken

By their early teens, most boys with DMD are wheelchair-bound.

❤️ Beyond Skeletal Muscle: Cardiac and Cognitive Involvement

DMD is not just about skeletal muscle. Two other systems are frequently involved:

Cardiac system:

• Dilated cardiomyopathy

• Arrhythmias, particularly conduction defects

• These are major causes of morbidity and mortality

Routine echocardiography and ECG monitoring are essential as part of follow-up.

Central nervous system:

• Cognitive impairment may be subtle or significant

• Dystrophin is also expressed in neurons, especially in areas responsible for cognition and emotional regulation

• Patients may have learning disabilities, attention deficits, or autism-like features

? How Is DMD Diagnosed?

Step 1: Creatine Kinase (CK) Level

• CK is massively elevated, often >10,000 IU/L

• Elevation precedes symptoms and reflects ongoing muscle breakdown

Step 2: Genetic Testing

• PCR or deletion/duplication analysis of the DMD gene

• Confirms the diagnosis and helps determine eligibility for targeted therapies

Optional: Muscle Biopsy

• Not required if genetic testing is conclusive

• Shows absence of dystrophin on immunohistochemistry

• May still be used in atypical cases or in resource-limited settings

? Genetic Inheritance and Counseling

DMD is X-linked recessive, so:

• Affected individuals are males

• Carrier females may pass the gene to 50% of sons (affected) and 50% of daughters (carriers)

• Genetic counseling and carrier testing are essential for families

? Management: Slowing the Progression

There is no cure, but early intervention can delay disability and improve survival.

Mainstay of therapy:

• Glucocorticoids
  • Prednisone or deflazacort
  • Improve muscle strength and function
  • Delay loss of ambulation
  • Delay scoliosis and cardiopulmonary complications
  • Side effects include weight gain, osteoporosis, and behavior changes

Cardiac care:

• ACE inhibitors and beta-blockers
  • Initiated even before symptoms, based on echocardiographic findings
  • Prevent or delay cardiomyopathy

Pulmonary care:

• Regular pulmonary function testing

• Non-invasive ventilation (BiPAP) in advanced stages

• Cough-assist devices and airway clearance strategies

Rehabilitation:

• Physical therapy to prevent contractures

• Bracing and assistive devices to maintain mobility

• Nutritional support, especially as dysphagia progresses

? Emerging Therapies: Gene-Targeted Options

Some DMD patients are eligible for mutation-specific therapies, like:

• Eteplirsen – an exon skipping agent (exon 51)
  • Helps restore the reading frame, allowing production of truncated but functional dystrophin

• Other exon-skipping or nonsense mutation read-through therapies are under investigation.

These therapies are not curative, but represent major advances in personalized medicine for DMD.

? Prognosis

Without treatment, most boys lose ambulation by age 12 and die in their 20s due to cardiopulmonary complications.

With early diagnosis, corticosteroids, and multidisciplinary care, survival into the 30s or beyond is possible.

? USMLE Step 2 CK High-Yield Summary

• Boy age 2–5 with proximal muscle weakness, Gowers’ sign, calf pseudohypertrophy

• CK >10,000 + DMD gene mutation = diagnosis

• X-linked recessive inheritance

• Cardiac and CNS involvement are common

• Steroids slow progression

• ACE inhibitors + beta-blockers for the heart

• Eteplirsen is a gene therapy option (exon 51)

• Death usually from respiratory or cardiac failure

? Final Words

Duchenne Muscular Dystrophy is a tragic yet well-understood genetic disease. Early diagnosis, aggressive medical care, and genetic counseling can profoundly change a patient’s journey — even when we cannot yet offer a cure.

On exams and in real life, remember: the boy who uses his hands to stand, the calves that look strong but aren’t, and the silent danger to the heart and lungs — these are the faces of Duchenne.

? Neuromyelitis Optica Spectrum Disorder (NMOSD)

Formerly known as Devic’s Disease

? Introduction: What Is NMOSD?

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe, immune-mediated demyelinating disease of the central nervous system, with a strong predilection for the optic nerves and the spinal cord.

Though NMOSD may look like multiple sclerosis (MS) in early stages, it is now recognized as a completely separate disease entity with its own antibody marker (AQP4-IgG), a different target cell (astrocytes), and a more severe clinical course.

For Step 2 CK and other board exams, NMOSD is a critical differential diagnosis when evaluating patients with optic neuritis and transverse myelitis.

? Pathophysiology: How Does NMOSD Work?

NMOSD is caused by autoantibodies directed against aquaporin-4 (AQP4) — a water channel protein found primarily on astrocyte foot processes at the blood-brain barrier.

When AQP4-IgG binds these astrocytes:

• It activates the complement cascade

• Causes astrocyte injury and death

• Leads to secondary demyelination, neuronal damage, and necrosis

This mechanism is distinct from MS, which primarily involves oligodendrocyte-targeted inflammation.

In AQP4-IgG-negative cases, some patients may test positive for anti-MOG (myelin oligodendrocyte glycoprotein) antibodies, a related but separate condition.

?‍⚕️ Clinical Features: What Do Patients Experience?

NMOSD usually presents with one or more of the following core syndromes, often in a relapsing pattern:

Optic Neuritis

• Presents with painful vision loss

• Often affects both eyes simultaneously or in rapid succession

• More likely than MS to cause permanent blindness

Longitudinally Extensive Transverse Myelitis (LETM)

• Characterized by spinal cord lesions extending over three or more vertebral segments

• Manifests as:

  • Paralysis or paresis

  • Numbness, tingling, and sensory level

  • Bladder or bowel dysfunction (urinary retention, constipation, incontinence)

Area Postrema Syndrome

• Occurs when the dorsal medulla is involved

• Classic features:

  • Intractable hiccups

  • Nausea and vomiting

Other Possible Features

• Brainstem syndromes (diplopia, dysphagia)

• Hypothalamic or diencephalic involvement

• Severe relapses that leave lasting disability

? How Is NMOSD Different from Multiple Sclerosis?

Understanding this distinction is vital for accurate diagnosis and appropriate treatment:

Antibodies and Target

• NMOSD involves AQP4-IgG antibodies targeting astrocytes

• MS involves no known autoantibody and targets oligodendrocytes

Optic Neuritis

• In NMOSD, it’s bilateral or sequential and more severe

• In MS, typically unilateral and milder with better recovery

Myelitis

• NMOSD causes longitudinally extensive lesions (≥3 segments)

• MS causes short-segment lesions

Brain Involvement

• NMOSD may show nonspecific or normal brain MRI early

• MS shows classic periventricular plaques, juxtacortical lesions, and Dawson fingers

CSF Findings

• NMOSD often lacks oligoclonal bands

• MS usually shows positive oligoclonal bands

Response to Treatment

• NMOSD worsens with MS treatments like interferon-beta or natalizumab

• MS improves with these drugs

? Diagnosis of NMOSD

The diagnosis requires a combination of clinical criteria, MRI, and serologic testing:

Step 1: Clinical Core Criteria

At least one of the following:

• Optic neuritis

• Acute myelitis

• Area postrema syndrome

• Acute brainstem or hypothalamic syndrome

Step 2: AQP4 Antibody Testing

• Cell-based assay for AQP4-IgG is highly specific

• Anti-MOG testing may be done if AQP4-IgG is negative

Step 3: MRI Findings

• Spinal MRI shows long lesions (≥3 vertebral segments)

• Optic nerve MRI may show chiasmal or longitudinal optic nerve involvement

• Brain MRI may be normal or involve hypothalamus, periependymal areas, or dorsal medulla

Step 4: CSF Analysis

• May show elevated protein and pleocytosis

• Oligoclonal bands typically absent

? Acute Management

First-line therapy:

• High-dose intravenous methylprednisolone

  • 1 gram daily for 3–5 days

If steroid-refractory:

• Plasmapheresis (PLEX) is effective in removing AQP4 antibodies and controlling the acute attack

Prompt treatment is essential to prevent permanent disability from a single relapse.

? Long-Term Management: Preventing Relapses

The focus is immunosuppression to prevent future attacks.

First-line therapies:

• Rituximab (anti-CD20 monoclonal antibody)
  • Depletes B cells and reduces AQP4 antibody levels
  • Effective and commonly used

• Azathioprine
  • A purine analog that suppresses lymphocyte function
  • Takes weeks to months to work

• Mycophenolate mofetil
  • Inhibits lymphocyte proliferation
  • Alternative to azathioprine

Targeted FDA-approved therapy:

• Eculizumab
  • Monoclonal antibody targeting complement C5
  • Specifically approved for AQP4-IgG positive NMOSD
  • Requires meningococcal vaccination due to infection risk

Critical caution:

• Avoid MS therapies like interferon-beta, natalizumab, and fingolimod — they can worsen NMOSD

? Prognosis

NMOSD carries a more severe prognosis than MS, especially if not treated early:

• Disability can occur after just one or two attacks

• Permanent blindness or paralysis is common in untreated cases

• Early and aggressive immunotherapy improves outcomes significantly

?  Exam Pearls

• Think of NMOSD in a patient with severe bilateral optic neuritis or longitudinal spinal cord lesion

• AQP4-IgG positivity confirms the diagnosis

• MRI shows ≥3 vertebral segments of myelitis

• Oligoclonal bands absent in CSF

• Treat acute flares with IV steroids, escalate to plasmapheresis if needed

• Use rituximab, azathioprine, or eculizumab for long-term prevention

• Avoid MS drugs — they can harm NMOSD patients

? Final Words

NMOSD is a high-stakes mimicker of multiple sclerosis — but the consequences of misdiagnosis are serious. Treating NMOSD like MS may cause more harm than good.

So remember: if you see severe optic neuritis, long spinal cord lesions, AQP4 positivity, and no oligoclonal bands — this is not MS. It’s NMOSD, and it needs immunosuppressive treatment, not disease-modifying MS drugs.

Accurate diagnosis means better outcomes, preserved vision, and preserved mobility.

? Introduction: What Is Friedreich Ataxia?

Friedreich ataxia is a rare, inherited neurodegenerative disorder that primarily affects the nervous system, musculoskeletal system, and heart. It is autosomal recessive in inheritance and typically presents in childhood or adolescence, making it a high-yield pediatric neurology topic for board exams.

This disease is defined by progressive ataxia, loss of deep tendon reflexes, and motor and sensory deficits, often accompanied by orthopedic abnormalities and serious cardiac complications.

it’s frequently tested in a vignette of a young patient with unsteady gait, foot deformities, and signs of hypertrophic cardiomyopathy.

? Genetic Cause and Pathophysiology

Friedreich ataxia is caused by a GAA trinucleotide repeat expansion in the frataxin (FXN) gene on chromosome 9.

Here’s what happens at the molecular level:

• The frataxin protein is normally involved in mitochondrial iron regulation and oxidative phosphorylation

• GAA expansion causes reduced expression of frataxin

• This leads to mitochondrial dysfunction, oxidative stress, and neuronal cell death, particularly in the dorsal root ganglia, spinocerebellar tracts, and corticospinal tracts

The result is a multisystem neurodegenerative disease affecting motor coordination, muscle strength, cardiac function, and endocrine organs.

? Which Neural Pathways Are Affected?

Several spinal cord and cerebellar pathways are damaged in Friedreich ataxia:

• Dorsal columns – leads to loss of proprioception and vibration sense

• Spinocerebellar tracts – causes gait and limb ataxia

• Lateral corticospinal tracts – results in motor weakness

• Dorsal root ganglia – leads to areflexia

This combination creates a mixed upper and lower motor neuron picture, with both sensory and motor deficits.

? Clinical Presentation

Friedreich ataxia typically begins before age 15, although late-onset forms exist. The progression is slow but relentless, leading to severe disability by early adulthood.

Key clinical features:

• Progressive gait ataxia – early sign; the patient appears clumsy, has difficulty walking

• Dysarthria – slurred or slow speech due to cerebellar dysfunction

• Limb weakness – lower limbs are more severely affected

• Loss of deep tendon reflexes – especially the ankle jerk

• Positive Romberg sign – reflects loss of proprioception

• Vibration and position sense loss – due to dorsal column degeneration

• Extensor plantar response (Babinski positive) – from corticospinal tract involvement

Orthopedic features:

• Pes cavus – high-arched foot, often bilateral

• Scoliosis or kyphoscoliosis – common and may be progressive

• Hammer toes – associated foot deformity

Cardiac involvement:

• Hypertrophic cardiomyopathy – the most serious complication

• May present with:

  • Palpitations

  • Arrhythmias

  • Syncope

  • Signs of heart failure

• Sudden cardiac death is a real concern

Endocrine involvement:

• Diabetes mellitus develops in about 10–20% of patients

• Caused by pancreatic β-cell dysfunction

? Diagnosis: How Is Friedreich Ataxia Confirmed?

Clinical suspicion:

• Young patient with gait instability, areflexia, foot deformities, and possibly cardiac symptoms

Step-by-step approach:

• Genetic testing – confirms diagnosis
  • Identifies GAA repeat expansion in the FXN gene

• Serum creatine kinase (CK) – may be mildly elevated

• MRI of the spinal cord – shows atrophy of the cervical spinal cord, especially the posterior columns

• Nerve conduction studies (NCS) – show mixed sensorimotor axonal neuropathy

• Electrocardiogram (ECG) and echocardiography – essential to evaluate for hypertrophic cardiomyopathy or conduction abnormalities

• Fasting glucose and HbA1c – screen for diabetes mellitus

? Differential Diagnoses to Consider

Although Friedreich ataxia is distinct, it may resemble other ataxic syndromes in early stages. Always distinguish from:

• Ataxia-telangiectasia – presents with oculocutaneous telangiectasias, immunodeficiency

• Vitamin E deficiency – similar neuro features but correctable

• Multiple sclerosis (in young adults) – relapsing-remitting, optic neuritis

• Spinocerebellar ataxias (SCA) – autosomal dominant, later onset

? Management and Prognosis

There is currently no cure for Friedreich ataxia. Management is supportive and multidisciplinary, aimed at maintaining function and reducing complications.

Supportive care includes:

• Physical therapy – to preserve mobility and delay contractures

• Occupational therapy – for activities of daily living

• Speech therapy – for dysarthria and swallowing assistance

• Orthopedic interventions – scoliosis bracing or corrective surgery if needed

• Cardiac monitoring – regular ECG and echocardiograms; treat cardiomyopathy with beta-blockers or ACE inhibitors as indicated

• Glycemic control – monitor and manage diabetes with diet, insulin, or oral agents

• Assistive devices – walkers, wheelchairs as needed in advanced stages

Experimental therapies:

• Idebenone – an antioxidant that may benefit cardiac and neurological function (limited efficacy; not widely adopted yet)

• Gene therapy and frataxin-targeted treatments – under investigation

? Prognosis

Friedreich ataxia is progressive and life-limiting:

• Wheelchair dependence often develops within 10–15 years of onset

• Cardiomyopathy is the leading cause of early death, usually by age 30–40

• Diabetes and respiratory complications may also contribute to morbidity

Early recognition and proactive multidisciplinary care can improve quality of life and extend survival.

? Exam Pearls

• Think of Friedreich ataxia in a child or teen with:
  • Progressive ataxia
  • Absent reflexes
  • Pes cavus or scoliosis
  • Cardiac signs (e.g., arrhythmias, hypertrophy)

• Diagnosis is confirmed by FXN gene testing showing GAA repeat expansion

• MRI shows spinal cord atrophy, not brain lesions

• Always evaluate the heart — sudden cardiac death is a major risk

• No curative treatment exists — focus on symptomatic care, cardiac monitoring, and genetic counseling

? Final Clinical Insight

Friedreich ataxia is a classic example of how a single gene mutation can cause a multisystem disorder affecting the nervous system, musculoskeletal system, heart, and pancreas.

It’s the child who can’t keep up with classmates, whose gait gets worse year by year, and who eventually needs a wheelchair and cardiac care — but still remains mentally alert and aware.

Your role as a clinician is to recognize the pattern early, confirm with genetic testing, and build a team around the patient to manage each system proactively.

? Neurocutaneous Syndromes (Phakomatoses)

Genetic Clues from the Skin to the Brain

? Introduction: Why Are These Syndromes Important?

Neurocutaneous syndromes, also called phakomatoses, are a group of genetic disorders characterized by simultaneous involvement of the skin and the nervous system.

Here’s the clinical pearl: these conditions often present with distinctive skin lesions that appear early in life, and they can be the first visible sign of serious underlying CNS pathology.

these are extremely high-yield because the vignette will often give you a child with a specific skin finding — and your job is to identify the syndrome and its associated complications.

? Core Features of Neurocutaneous Syndromes

• Autosomal dominant inheritance (except for Sturge-Weber, which is sporadic)

• Early cutaneous manifestations that lead to neurologic diagnosis

• Risk of CNS tumors, seizures, intellectual disability, and organ involvement

• Diagnosis is often clinical, supported by genetic testing and neuroimaging

• Early identification allows surveillance and prevention of complications

? Neurofibromatosis Type 1 (NF1)

Cause:

• Mutation in the NF1 gene on chromosome 17

• Encodes neurofibromin, a tumor suppressor protein

Inheritance:

• Autosomal dominant with complete penetrance, variable expressivity

Classic Skin Findings:

• Café-au-lait macules – flat, hyperpigmented spots
  • Diagnostic if ≥6 spots ≥5 mm in children or ≥15 mm in adults

• Axillary or inguinal freckling – known as Crowe sign

• Cutaneous neurofibromas – soft, flesh-colored, dome-like lesions

• Lisch nodules – hamartomas seen in the iris on slit-lamp exam

Neurological & Systemic Involvement:

• Optic gliomas – can cause vision loss

• Seizures or learning disabilities

• Pheochromocytoma – episodic hypertension, tremors

• Scoliosis, tibial dysplasia

Clinical Tip:

• Always evaluate the eye and CNS imaging in patients with ≥6 café-au-lait spots

? Neurofibromatosis Type 2 (NF2)

Cause:

• Mutation in the NF2 gene on chromosome 22

• Encodes merlin (also called schwannomin)

Inheritance:

• Autosomal dominant

Key Features:

• Bilateral vestibular schwannomas (acoustic neuromas) – hallmark
  • Present with hearing loss, tinnitus, imbalance, and facial numbness

• May also have spinal cord tumors, meningiomas, or ependymomas

Skin Findings:

• Fewer than NF1

• May include cutaneous schwannomas or plaque-like lesions

Clinical Tip:

• Think NF2 in a young adult with bilateral sensorineural hearing loss

? Tuberous Sclerosis Complex (TSC)

Cause:

• Mutation in TSC1 (hamartin) or TSC2 (tuberin) gene

• Leads to hamartoma formation in multiple organs

Inheritance:

• Autosomal dominant

Cutaneous Clues:

• Ash leaf spots – hypopigmented macules seen best under Wood’s lamp

• Facial angiofibromas (adenoma sebaceum) – reddish papules on the cheeks and nose

• Shagreen patch – leathery, thickened skin over the lumbosacral area

• Periungual fibromas – small, fleshy growths near fingernails/toenails

Neurological Features:

• Cortical tubers – malformed gyri; contribute to seizures

• Subependymal nodules – along the lateral ventricles

• Subependymal giant cell astrocytomas (SEGA) – may obstruct CSF flow

• Infantile spasms, intellectual disability, autism spectrum features

Systemic Involvement:

• Renal angiomyolipomas

• Cardiac rhabdomyomas – seen on fetal echocardiogram

• Pulmonary lymphangioleiomyomatosis (LAM) in adult females

Clinical Tip:

• Suspect TSC in a child with seizures, facial angiofibromas, and hypopigmented macules

? Sturge-Weber Syndrome

Cause:

• Sporadic, due to a somatic mutation in the GNAQ gene

Hallmark Feature:

• Facial port-wine stain in the distribution of the trigeminal nerve (V1)
  • Does not cross midline
  • Present at birth

Neurologic Features:

• Leptomeningeal angiomas – vascular malformations on brain surface

• Seizures – often focal and drug-resistant

• Hemiparesis or developmental delay

• Cortical calcifications – “tram-track” appearance on CT

Ophthalmic Findings:

• Glaucoma – due to increased episcleral venous pressure

Clinical Tip:

• Any infant with a V1 facial port-wine stain needs brain imaging and ophthalmologic evaluation

? Von Hippel–Lindau (VHL) Disease

Cause:

• Mutation in the VHL tumor suppressor gene on chromosome 3

Inheritance:

• Autosomal dominant

Key Features:

• Hemangioblastomas of the cerebellum and retina
  • May cause vision changes or ataxia

• Renal cell carcinoma (clear cell type) – commonly bilateral

• Pheochromocytoma – screen for hypertension

• Pancreatic cysts and neuroendocrine tumors

Skin Findings:

• Typically absent, unlike other phakomatoses

Clinical Tip:

• Think VHL in a young adult with cerebellar symptoms, retinal lesions, and a family history of kidney cancer

? Summary of Core Associations

Let’s solidify the pattern recognition approach for Step 2 CK vignettes:

• NF1 = Café-au-lait spots, axillary freckles, Lisch nodules, optic glioma, neurofibromas

• NF2 = Bilateral vestibular schwannomas, merlin gene mutation, few skin findings

• TSC = Ash leaf spots, facial angiofibromas, seizures, cardiac and renal hamartomas

• Sturge-Weber = Facial port-wine stain, leptomeningeal angiomas, seizures, glaucoma

• VHL = Cerebellar and retinal hemangioblastomas, renal carcinoma, pheochromocytoma

? Exam Pearls

• Always inspect the skin in any child with seizures or developmental delay

• Facial port-wine stain + seizures = Sturge-Weber

• Ash leaf spots + infantile spasms = Tuberous sclerosis

• Café-au-lait macules + optic glioma = NF1

• Bilateral hearing loss + spinal tumors = NF2

• Cerebellar mass + renal cancer = VHL

? Final Clinical Insight

Neurocutaneous syndromes offer one of the few opportunities in medicine where skin findings serve as windows into the brain. Recognizing these dermatologic clues can lead to early diagnosis, lifesaving surveillance, and timely treatment of serious neurologic or systemic complications.

In exams and real life, always look at the skin before you scan the brain.

⚡ Trigeminal Neuralgia

A High-Yield Pain Syndrome of the Face

? What Is Trigeminal Neuralgia?

Trigeminal neuralgia, also known by its historical name tic douloureux, is a chronic pain disorder involving the trigeminal nerve (cranial nerve V). It is characterized by recurrent, sudden, and severe stabbing pain in the face, typically lasting for seconds to minutes, and occurring in paroxysms.

it is tested frequently through case vignettes describing electric shock-like facial pain triggered by simple stimuli like chewing, talking, tooth brushing, or even cold wind.

The disorder most commonly affects the maxillary (V2) and mandibular (V3) divisions of the trigeminal nerve. The ophthalmic branch (V1) is rarely involved.

? Pathophysiology

The most common cause is vascular compression of the trigeminal nerve root at its entry into the brainstem, typically by an aberrant loop of the superior cerebellar artery. This leads to:

• Demyelination of the nerve fibers

• Hyperexcitability of the nerve

• Ectopic firing and ephaptic transmission, causing paroxysmal pain

Secondary causes include:

• Multiple sclerosis – especially in young patients or those with bilateral facial pain

• Tumors at the cerebellopontine angle – such as acoustic neuromas or meningiomas

• Post-traumatic changes, or vascular malformations

?‍⚕️ Clinical Presentation

The diagnosis is often straightforward, based on classic symptoms.

Key features:

• Sudden, sharp, stabbing pain — often described as an electric shock

• Unilateral facial involvement, especially in V2 and V3

• Each episode lasts seconds to a few minutes, with pain-free intervals

• Triggered by routine actions such as:

  • Brushing teeth

  • Chewing

  • Talking

  • Cold air or facial touch

Important findings:

• No sensory loss between attacks — neurological exam is usually normal

• During an episode, the patient may grimace, wince, or hold their face, which is where the term “tic” originates

• Patients often live in fear of triggering the next painful burst

? Diagnosis

Trigeminal neuralgia is primarily a clinical diagnosis, based on:

• Classic paroxysmal facial pain

• Triggering stimuli

• Normal neurologic exam

When to image:

• MRI with contrast is indicated when:

  • The patient is young

  • Symptoms are bilateral

  • Pain is constant, or progressive, rather than episodic

  • There are neurological deficits

MRI helps exclude secondary causes such as:

• Multiple sclerosis plaques

• Tumors compressing the trigeminal nerve

• Vascular malformations

? Management

First-line treatment:

• Carbamazepine
  • Mechanism: blocks voltage-gated sodium channels, reducing nerve firing
  • Rapidly effective — response to carbamazepine supports the diagnosis
  • Monitor CBC and LFTs due to risk of:

  • Aplastic anemia

  • Agranulocytosis

  • Hepatotoxicity

Alternatives:

• Oxcarbazepine – similar efficacy, better tolerated

• Gabapentin, lamotrigine, and baclofen may be considered for resistant cases

In refractory cases:

• Surgical options include:

  • Microvascular decompression – relieves the vascular compression of the trigeminal nerve root; often the most effective long-term solution

  • Radiofrequency ablation or gamma knife radiosurgery – destroy portions of the trigeminal nerve to reduce pain; may cause facial numbness

  • Glycerol injection or balloon compression – minimally invasive procedures to damage the nerve and reduce pain transmission

? High-Yield Pearls

• Think trigeminal neuralgia when you read: unilateral, sharp, electric facial pain triggered by chewing or touch

• Most common in older women

• Caused by vascular compression of the trigeminal nerve root

• Always image with MRI in younger patients, bilateral cases, or when symptoms deviate from the classic picture

• Carbamazepine is first-line — both diagnostic and therapeutic

• Microvascular decompression is the preferred surgical approach for medically refractory cases

? Final Clinical Insight

Trigeminal neuralgia is one of the most excruciating pain syndromes in neurology — but it is also very treatable when diagnosed correctly.

While the pain can be brief, the impact on quality of life is profound. As a clinician, your job is to recognize the pattern, rule out secondary causes, and initiate appropriate treatment early to spare the patient unnecessary suffering.

On your Step 2 CK exam and in clinical practice, if you see a patient who is afraid to eat, talk, or touch their face due to lightning-like pain, always think:
Could this be trigeminal neuralgia?

? Huntington’s Disease (Huntington’s Chorea)

Progressive, Genetic Neurodegeneration with Chorea and Cognitive Decline

? Introduction: What Is Huntington’s Disease?

Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder, classically defined by a triad:

• Chorea – involuntary, jerky, non-rhythmic movements

• Psychiatric symptoms – mood, personality, or psychotic features

• Cognitive decline – including memory loss, poor judgment, and executive dysfunction

This condition is high-yield for Step 2 CK, especially when presented as a middle-aged adult with abnormal movements, psychiatric symptoms, and a family history of similar illness, often affecting a parent in early mid-life.

? Genetic Cause and Inheritance

Huntington’s disease is caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4.

Let’s break it down:

• CAG codes for glutamine → leads to polyglutamine expansion

• The abnormal mutant huntingtin protein accumulates in neurons

• This causes neuronal death, especially in the caudate nucleus and putamen (components of the striatum)

• Excitotoxicity and dopaminergic imbalance contribute to motor dysfunction

Key genetic fact:

• 36 CAG repeats = diagnostic

• The higher the repeat number, the earlier the onset (called anticipation — especially prominent when inherited from the father)

? Pathophysiology and Brain Changes

• The primary site of degeneration is the neostriatum (caudate + putamen)

• Loss of GABAergic inhibitory neurons leads to hyperkinetic movements

• Over time, progressive cortical atrophy contributes to dementia

• On MRI, the caudate nucleus shrinks, causing enlargement of the lateral ventricles

?‍⚕️ Clinical Features

Age of onset:

• Most patients develop symptoms between ages 30 and 50

• Rare juvenile-onset forms (Westphal variant) may present with bradykinesia and rigidity instead of chorea

Initial presentation:

• Psychiatric symptoms often appear first:
  • Depression, anxiety, apathy, or irritability
  • Obsessive-compulsive behaviors
  • Psychosis or paranoia in some cases

• Cognitive symptoms:
  • Early changes in executive function (e.g., decision-making, planning)
  • Later progresses to dementia, poor concentration, memory loss

• Motor symptoms:
  • Chorea – brief, irregular, jerky movements of face, limbs, trunk
  • Fidgetiness, facial grimacing, shoulder jerks
  • Imbalance and gait disturbance
  • Speech changes, dysarthria, and dysphagia

Late-stage features:

• Rigidity

• Bradykinesia – resembling Parkinsonism

• Incontinence

• Severe dementia

• Profound disability and full dependence

Suicide risk:

• Suicide is significantly elevated, especially during early and middle stages when patients have insight into their decline

? Diagnosis

Diagnosis is based on clinical suspicion and confirmed by genetic testing.

Step-by-step approach:

• Clinical suspicion in any patient with:
  • Progressive chorea
  • Psychiatric and cognitive changes
  • Family history of similar symptoms

• Genetic testing:
  • Detects CAG repeat expansion (>36 repeats) in the HTT gene

• MRI brain:
  • Shows caudate atrophy and enlarged lateral ventricles

• Cognitive assessment tools (e.g., MMSE, MoCA) may help quantify decline

? Differential Diagnoses

Always consider the following when evaluating hyperkinetic movement disorders:

• Wilson’s disease – especially in younger patients; check ceruloplasmin and LFTs

• Sydenham chorea – post-streptococcal; seen in children

• Drug-induced dyskinesia – e.g., from antipsychotics or levodopa

• Juvenile myoclonic epilepsy, Tourette’s syndrome, early-onset Parkinsonism

? Management and Treatment

There is currently no cure for Huntington’s disease. Management focuses on symptom control, preserving function, and supportive care.

For chorea:

• Tetrabenazine or deutetrabenazine
  • Depletes presynaptic dopamine by inhibiting VMAT2
  • Reduces choreiform movements
  • Side effects: sedation, depression, parkinsonism

• Atypical antipsychotics (e.g., risperidone, olanzapine)
  • Useful for both chorea and behavioral symptoms
  • May be preferred in patients with concurrent psychosis or agitation

For psychiatric symptoms:

• SSRIs for depression and anxiety

• Mood stabilizers (e.g., valproate, carbamazepine) for mood swings

• Antipsychotics if delusions, hallucinations, or severe agitation

? Multidisciplinary Support

A comprehensive care plan should include:

• Neurologist – for movement disorder management

• Psychiatrist or psychologist – for psychiatric care and suicide prevention

• Physical and occupational therapists – to preserve mobility and ADLs

• Speech and language pathologist – for dysphagia and dysarthria

• Genetic counseling – for family members and future planning

• Social work and palliative care – to support long-term needs

? Prognosis

Huntington’s disease is progressive and ultimately fatal.

• Average survival after onset is 15–20 years

• Death is often due to:
  • Aspiration pneumonia
  • Malnutrition
  • Falls and trauma
  • Suicide

Early diagnosis allows patients and families to make advanced care decisions, including living arrangements, feeding options, and end-of-life planning.

? High-Yield Summary

• Think Huntington’s in a middle-aged adult with:
  • Chorea
  • Mood or personality changes
  • Family history of similar symptoms

• Caused by CAG repeat expansion on chromosome 4

• Affects caudate and putamen → chorea and dementia

• Genetic testing confirms diagnosis

• Tetrabenazine reduces chorea

• Antipsychotics and SSRIs manage psychiatric symptoms

• Always assess for suicidality

• No cure — care is supportive and multidisciplinary

? Final Clinical Insight

Huntington’s disease is a devastating, hereditary illness that presents a complex mix of neurology, psychiatry, and genetics. Early in its course, it may mimic depression or anxiety. Later, it resembles Parkinsonism and dementia.

The most powerful clue is the family history. Always ask.

As a clinician, your role is to guide the patient and their family through a journey of early recognition, symptom management, and compassionate care — every step of the way.

? Autonomic Neuropathy

Dysfunction Across Systems – Recognizing the Invisible Nervous System

? Introduction: What Is Autonomic Neuropathy?

Autonomic neuropathy refers to damage or dysfunction of the autonomic nervous system (ANS) — the part of the nervous system responsible for involuntary bodily functions, including heart rate, blood pressure, digestion, urination, sexual function, and thermoregulation.

This condition becomes highly relevant on USMLE Step 2 CK, especially in patients with diabetes mellitus who present with unexplained, multisystem complaints.

The autonomic nervous system includes:

• Sympathetic fibers – control “fight or flight” responses

• Parasympathetic fibers – regulate “rest and digest” functions

• Enteric nervous system – coordinates gastrointestinal motility

? Causes of Autonomic Neuropathy

Most common cause:

• Diabetes mellitus – both type 1 and type 2

Other notable causes:

• Amyloidosis

• Parkinson’s disease

• Guillain-Barré syndrome – especially Miller Fisher variant

• Chronic alcoholism

• HIV/AIDS

• Medications or toxins – e.g., chemotherapeutic agents, heavy metals, anticholinergics

? Clinical Manifestations: Systems Affected

Autonomic neuropathy is multisystemic and presents with a diverse range of symptoms depending on which branch of the ANS is affected. Let’s break them down system by system:

Cardiovascular:

• Orthostatic hypotension
  • Defined as a drop in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg within 3 minutes of standing
  • Often causes lightheadedness, dizziness, or syncope

• Resting tachycardia
  • Due to unopposed sympathetic tone

• Blunted heart rate variability
  • Abnormal response to physiologic stressors such as breathing or positional change

Gastrointestinal:

• Gastroparesis
  • Presents with early satiety, nausea, bloating, and vomiting
  • Often worsens postprandially

• Constipation or diarrhea
  • Due to disrupted enteric nervous system control

• Fecal incontinence
  • A distressing late complication in severe neuropathy

Genitourinary:

• Neurogenic bladder
  • Causes urinary retention, incomplete emptying, or overflow incontinence

• Erectile dysfunction
  • Due to impaired parasympathetic input

• Retrograde ejaculation
  • Semen enters the bladder rather than exiting through the urethra

Metabolic and Thermoregulatory:

• Anhidrosis
  • Decreased sweating, often leading to heat intolerance

• Hypoglycemia unawareness
  • Diabetics lose early warning symptoms of low blood sugar (like tremors or palpitations)
  • Can lead to severe, unrecognized hypoglycemia — a life-threatening emergency

? Diagnosis

The diagnosis of autonomic neuropathy is largely clinical, based on a detailed history and recognition of characteristic symptoms. However, specific tests can help confirm and quantify the dysfunction.

Autonomic function testing includes:

• Heart rate response to deep breathing
  • Assesses vagal (parasympathetic) tone

• Valsalva maneuver
  • Evaluates baroreflex sensitivity

• Tilt-table testing
  • Identifies orthostatic hypotension and helps distinguish neurogenic vs non-neurogenic causes

Additional evaluations:

• Gastric emptying study
  • Used in suspected gastroparesis to confirm delayed gastric motility

• Urodynamic studies
  • Evaluate bladder function and detrusor activity

• Continuous glucose monitoring
  • Helps identify episodes of hypoglycemia unawareness in diabetic patients

? Management Approach

General Principles:

• Address the underlying cause (e.g., optimize diabetic control)

• Provide symptomatic relief for specific system involvement

• Use a multidisciplinary approach including neurology, endocrinology, cardiology, and gastroenterology

Management by System:

For Orthostatic Hypotension:

• Non-pharmacologic:
  • Increase salt and fluid intake
  • Use compression stockings
  • Elevate the head of the bed at night
  • Encourage slow position changes

• Pharmacologic:
  • Fludrocortisone – mineralocorticoid that increases blood volume
  • Midodrine – alpha-1 agonist that increases vascular tone
  • Others: droxidopa, pyridostigmine (off-label use)

For Gastroparesis:

• Dietary modifications: small, frequent, low-fat meals

• Prokinetic agents:
  • Metoclopramide – dopamine antagonist; risk of tardive dyskinesia
  • Erythromycin – macrolide antibiotic that stimulates motilin receptors
  • Domperidone (used in some countries but not FDA-approved in the US)

For Bladder Dysfunction:

• Scheduled voiding or intermittent catheterization

• Bethanechol – cholinergic agent to enhance detrusor contraction

• Anticholinergics (e.g., oxybutynin) for overactive bladder symptoms (if present)

For Erectile Dysfunction:

• Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil)

• Vacuum erection devices or intracavernosal injections in refractory cases

For Hypoglycemia Unawareness:

• Adjust insulin regimen

• Continuous glucose monitoring

• Educate on early dietary and behavioral interventions

? USMLE Step 2 CK High-Yield Summary

• Autonomic neuropathy = multisystem dysfunction of involuntary bodily processes

• Most common cause is diabetes mellitus

• Classic symptoms include:
  • Orthostatic hypotension
  • Gastroparesis
  • Bladder dysfunction
  • Erectile dysfunction
  • Hypoglycemia unawareness

• Diagnosis is clinical, but may be supported with:
  • Tilt-table test
  • Heart rate variability
  • Gastric emptying study

• First-line treatment for orthostatic hypotension: fluid/salt, compression, then fludrocortisone/midodrine

• Metoclopramide or erythromycin can improve gastric motility

• PDE-5 inhibitors for erectile dysfunction

• Always monitor for severe hypoglycemia in diabetics with autonomic involvement

? Final Clinical Insight

Autonomic neuropathy often presents subtly, but its impact on quality of life — and even mortality — is profound. It's not just about fainting or digestion. When a diabetic loses the ability to feel hypoglycemia, the consequences can be fatal.

Your clinical responsibility is to recognize the constellation of vague symptoms, connect them to autonomic dysfunction, and manage each domain with precision and empathy.

In exams and in real life, when a patient presents with weird multisystem complaints that don’t seem to fit together — always think:
Could this be autonomic neuropathy?

? Subarachnoid Hemorrhage (SAH)

A High-Stakes Neurologic Emergency

? Introduction: What Is SAH?

Subarachnoid hemorrhage (SAH) is a neurological emergency caused by bleeding into the subarachnoid space—the area between the arachnoid and pia mater that surrounds the brain and spinal cord.

On USMLE Step 2 CK, SAH is a high-yield diagnosis, often presented through a dramatic clinical vignette involving a patient with a sudden, severe headache followed by nausea, neck stiffness, photophobia, or loss of consciousness.

While trauma can cause SAH, the most common non-traumatic cause is rupture of a saccular (berry) aneurysm at the circle of Willis.

? Common Causes of SAH

Most common:

• Ruptured berry aneurysm – usually at branch points of the circle of Willis

Less common:

• Arteriovenous malformations (AVMs)

• Trauma

• Mycotic aneurysms

• Bleeding disorders or anticoagulation

• Cocaine use – due to transient severe hypertension

⚠️ Risk Factors

• Hypertension

• Smoking

• Family history of intracranial aneurysms

• Autosomal dominant polycystic kidney disease (ADPKD)

• Coarctation of the aorta

• Connective tissue disorders like Ehlers-Danlos syndrome or Marfan syndrome

These patients should be carefully screened if they present with neurologic symptoms or severe headaches.

? Clinical Presentation

Key hallmark:

• Thunderclap headache
  • Sudden, severe, and maximal at onset
  • Described as the "worst headache of my life"

Associated features:

• Nausea and vomiting

• Photophobia

• Neck stiffness – due to meningeal irritation

• Brief loss of consciousness

• Seizures

• Focal neurological deficits – may reflect aneurysm location or complications like vasospasm

• Third cranial nerve palsy (ptosis, "down and out" eye, fixed dilated pupil)
  • Suggests posterior communicating artery aneurysm

? Physical Examination Findings

• Nuchal rigidity – neck stiffness from blood in CSF

• Positive Brudzinski or Kernig sign – meningeal irritation

• Altered mental status – due to increased ICP or diffuse bleeding

• Cranial nerve abnormalities

• Papilledema – from raised intracranial pressure

Despite dramatic symptoms, neurologic exam may be normal between episodes, especially in small sentinel bleeds (warning leaks that precede major hemorrhage).

? Diagnostic Approach

Step 1: Emergent Non-Contrast Head CT

• Best initial test

• Highly sensitive within first 6 hours of symptom onset

• Detects blood in subarachnoid space (especially in basal cisterns and sulci)

Step 2: Lumbar Puncture (LP)

• Indicated if CT is negative but clinical suspicion remains high

• Look for:
  • Xanthochromia – yellow discoloration of CSF due to bilirubin breakdown
  • Elevated opening pressure
  • RBCs in all tubes

Xanthochromia may take 6–12 hours to develop, but remains positive for days.

Step 3: CT Angiography or MR Angiography

• Performed after SAH is confirmed to locate the source of bleeding

• Guides definitive treatment planning (clipping vs coiling)

?️ Initial Management

ICU admission:

• All patients require intensive monitoring for:
  • Blood pressure control
  • Neurological deterioration
  • Hydrocephalus or vasospasm
  • Seizures and electrolyte abnormalities

Blood pressure control:

• Aim to prevent rebleeding

• Maintain systolic BP <160 mmHg

• Preferred agents:
  • Labetalol – beta-blocker
  • Nicardipine – calcium channel blocker
  • Avoid nitroprusside – may increase ICP

? Preventing Complications

1. Vasospasm (Delayed Cerebral Ischemia)

• Occurs 4–14 days post-hemorrhage

• Leads to secondary strokes

• Prevented by Nimodipine, a calcium channel blocker
  • Improves neurologic outcomes
  • Started in all patients with aneurysmal SAH

2. Rebleeding

• Most likely to occur within first 24 hours

• Reduced by early surgical intervention

3. Hydrocephalus

• Blood obstructs CSF flow

• Causes ventricular dilation, headache, confusion

• Managed with external ventricular drain (EVD) if symptomatic

4. Hyponatremia

• May be due to SIADH or cerebral salt wasting

• Requires careful volume status assessment
  • SIADH → fluid restriction
  • Salt wasting → fluid and salt repletion

5. Seizures

• May occur early or during recovery

• Anticonvulsants are not routinely used prophylactically, but are given if seizures occur

? Definitive Treatment: Securing the Aneurysm

Options include:

• Surgical clipping
  • Involves craniotomy and placing a clip across aneurysm neck
  • Preferred for accessible, large, or irregular aneurysms

• Endovascular coiling
  • Catheter-based procedure filling the aneurysm with platinum coils
  • Minimally invasive; often preferred in older patients or those with high surgical risk

Decision is made by neurosurgery or interventional neuroradiology based on aneurysm location, size, and patient factors.

? Prognosis

Prognosis depends on:

• Severity at presentation – quantified by Hunt and Hess scale

• Extent of bleeding

• Timeliness of treatment

• Development of complications

Poor prognostic signs:

• Loss of consciousness at onset

• Severe neurologic deficits

• Rebleeding

• Vasospasm-induced infarction

Survivors may have long-term cognitive and physical impairments, even with good recovery.

? USMLE Step 2 CK High-Yield Summary

• Sudden, severe headache = "thunderclap" → suspect SAH

• First test: non-contrast head CT

• If CT is negative and suspicion is high → LP for xanthochromia

• Source of bleed = ruptured berry aneurysm

• CT angiography follows diagnosis to locate aneurysm

• Nimodipine prevents vasospasm and improves outcomes

• Definitive treatment = surgical clipping or endovascular coiling

• Monitor for hydrocephalus, hyponatremia, rebleeding, seizures

• Avoid agents that increase ICP (e.g., nitroprusside)

? Final Clinical Insight

Subarachnoid hemorrhage is a diagnosis you cannot afford to miss. A healthy young adult with sudden severe headache, collapse, or seizure should raise immediate concern for SAH.

Your first move is rapid imaging. Your second move is life-saving intervention.

Always remember:
If a patient says “worst headache of my life”,
Your answer should be “CT head now.”

? Brown-Séquard Syndrome

A Classic Hemisection Syndrome – Neuroanatomy in Real Life

? Introduction: What Is Brown-Séquard Syndrome?

Brown-Séquard Syndrome is a hemisection of the spinal cord, meaning injury to one half of the spinal cord (right or left), resulting in a characteristic pattern of motor and sensory loss that reflects the underlying tract anatomy.

This condition is rare, but highly testable — because its symptoms neatly map onto spinal cord pathways, making it one of the most classically described neurologic syndromes in clinical medicine and on USMLE Step 2 CK.

? Etiology: What Causes It?

Most common cause:

• Penetrating spinal trauma — such as a stab wound or gunshot injury

Other causes include:

• Spinal tumors (e.g., meningioma, ependymoma)

• Epidural hematoma

• Spinal cord ischemia

• Infectious or inflammatory lesions

• Multiple sclerosis – can mimic Brown-Séquard in demyelinating plaques

While traumatic causes tend to present suddenly, non-traumatic etiologies often cause progressive symptoms.

? Neuroanatomy Breakdown

Understanding Brown-Séquard Syndrome means knowing which spinal cord tracts are affected and where they cross.

Let’s focus on the three major tracts involved:

1. Corticospinal Tract (Motor Pathway)

• Carries voluntary motor signals

• Decussates (crosses) in the medullary pyramids

• So, a hemisection causes ipsilateral motor weakness below the level of the lesion

• Leads to spastic paralysis, hyperreflexia, and positive Babinski sign

2. Dorsal Columns

• Carry proprioception, vibration, and fine touch

• Ascend ipsilaterally and cross in the medulla

• So, damage causes ipsilateral loss of position sense and vibration below the lesion

3. Spinothalamic Tract

• Transmits pain and temperature sensation

• Crosses over 1–2 spinal segments after entry

• So, damage to one side of the cord causes contralateral loss of pain and temperature, starting a few levels below the lesion

? Classic Clinical Findings

The hallmark triad:

• Ipsilateral motor loss (due to corticospinal tract damage)

• Ipsilateral loss of vibration and proprioception (due to dorsal column damage)

• Contralateral loss of pain and temperature (due to spinothalamic tract damage)

Additional findings:

• Segmental signs at the level of the lesion:
  • Flaccid paralysis
  • Decreased or absent reflexes
  • Due to damage to anterior horn cells or nerve roots

• Bladder and bowel function:
  • Usually preserved, unless the lesion is very high, extensive, or bilateral

Onset:

• Often acute in trauma

• Patients may say:
  • “One side of my body is weak”
  • “The other side feels numb or burning”
  • May have gait imbalance or sensory dissociation

? Diagnosis

Step 1: Clinical Neurologic Examination

• Key to suspecting Brown-Séquard — based on the asymmetric pattern of motor and sensory loss

Step 2: MRI of the Spine

• Confirms the location and extent of cord involvement

• Detects underlying cause:
  • Trauma, tumor, hematoma, demyelination, or abscess

MRI is essential in non-traumatic cases to rule out treatable structural lesions

Step 3: Additional workup

• CT myelogram – if MRI is contraindicated

• CSF analysis – if MS or infection is suspected

• Spine angiography – if spinal vascular malformation is suspected

?️ Management

For traumatic Brown-Séquard:

• Initial stabilization – ABCs and spinal precautions

• High-dose corticosteroids – previously recommended (now controversial)

• Surgical decompression – if there's compressive lesion or unstable spine

• Neurorehabilitation – physical and occupational therapy

For non-traumatic causes:

• Surgical resection or decompression – for tumors or hematoma

• Antibiotics or antivirals – if infectious

• Steroids/immunotherapy – for MS or autoimmune causes

Supportive care:

• Pain control

• Spasticity management

• DVT prophylaxis

• Bladder training if necessary

? Prognosis

Brown-Séquard syndrome has a relatively favorable prognosis compared to complete spinal cord injuries:

• Most patients regain ambulatory function

• Prognosis is best with incomplete lesions

• Early physical therapy is essential to optimize recovery

However, persistent sensory deficits or weakness may remain depending on the cause and delay in treatment.

? USMLE Step 2 CK High-Yield Summary

• Brown-Séquard = hemisection of the spinal cord

• Most commonly from penetrating trauma

• Ipsilateral findings:
  • Motor loss (spastic paralysis)
  • Loss of vibration and proprioception

• Contralateral findings:
  • Loss of pain and temperature, starting a few segments below

• Diagnosis confirmed with MRI of the spine

• Management = surgical decompression if needed + rehabilitation

• Prognosis = good with early treatment

? Final Clinical Insight

Brown-Séquard Syndrome is not just a board question — it’s a perfect example of anatomy meeting clinical reality.

When a patient has asymmetric weakness and a sensory split pattern, always consider a spinal cord lesion, and think in terms of the tracts and where they cross.

On exam day or in real life, if one leg is weak with no vibration, and the other leg burns with no pain perception, your answer is:

“Brown-Séquard Syndrome – get an MRI.”

? Restless Leg Syndrome (RLS) – Willis–Ekbom Disease

A Sleep-Related Movement Disorder with Sensory Clues

? Introduction: What Is Restless Leg Syndrome?

Restless Leg Syndrome (RLS), also called Willis–Ekbom Disease, is a sensorimotor neurologic disorder that causes an uncomfortable urge to move the legs, usually during periods of rest or inactivity, particularly in the evening or at night. The symptoms are relieved by movement, such as walking or stretching.

On USMLE Step 2 CK, RLS frequently appears in sleep disorder questions, especially in patients with insomnia, fatigue, or sleep disruption, often with otherwise normal laboratory results.

The condition may be primary (idiopathic) or secondary to a wide range of medical causes, including iron deficiency, pregnancy, or renal disease.

? Core Symptoms and Diagnostic Criteria

Diagnosis of RLS is clinical, based on the following four cardinal features:

1. Urge to move the legs — often associated with uncomfortable sensations such as tingling, crawling, pulling, or aching

2. Symptoms begin or worsen during rest or inactivity — such as sitting or lying down

3. Relief of symptoms with movement — temporary relief by walking or stretching

4. Worsening of symptoms in the evening or night — typically disrupts sleep or relaxation time

These features distinguish RLS from other forms of leg discomfort or neuropathy. Patients may say they “can’t keep their legs still” at night, leading to fragmented sleep, fatigue, and even mood changes.

? Types of RLS

1. Primary (Idiopathic) RLS

• Often familial, with a genetic predisposition

• Onset may occur in childhood or young adulthood

• Tends to progress slowly over time

2. Secondary RLS

Occurs in association with other medical conditions or medications. Important secondary causes include:

• Iron deficiency – even if hemoglobin is normal

• Pregnancy, especially in the third trimester

• Chronic kidney disease (uremia)

• Diabetes mellitus

• Multiple sclerosis

• Rheumatoid arthritis

• Peripheral neuropathy

Medication-induced RLS:

• SSRIs (e.g., fluoxetine, sertraline)

• Dopamine antagonists (e.g., antipsychotics, metoclopramide)

• First-generation antihistamines (e.g., diphenhydramine)

• Tricyclic antidepressants

Identifying and withdrawing offending medications is a critical part of evaluation.

? Evaluation and Workup

Although diagnosis is clinical, evaluation should include screening for reversible causes, especially iron deficiency.

Key steps:

• Serum ferritin – to evaluate iron stores
  • Even in the presence of normal hemoglobin, ferritin <75 ng/mL is considered insufficient in RLS
  • Iron deficiency is a common and treatable trigger

• Neurologic exam – typically normal

• Polysomnography (sleep study) – not required for diagnosis, but may reveal periodic limb movements of sleep (PLMS)

• No imaging or nerve conduction studies are needed unless other neurological signs are present

⚙️ Management Strategy

Step 1: Non-Pharmacologic Interventions

• Avoid caffeine, alcohol, and nicotine

• Stop or adjust offending medications (e.g., SSRIs, antihistamines)

• Maintain consistent sleep hygiene

• Encourage daily moderate exercise

• Address underlying iron deficiency or systemic illness

Step 2: Iron Supplementation

• Oral iron (ferrous sulfate) is given if ferritin is <75 ng/mL

• Co-administer with vitamin C to enhance absorption

• IV iron may be considered in refractory or malabsorptive cases

Step 3: Pharmacologic Treatment

For moderate to severe symptoms that impair sleep or quality of life:

Dopamine agonists – first-line for most patients

• Pramipexole

• Ropinirole

Mechanism: Stimulate dopamine receptors to reduce sensory urge and movement

Note: Long-term use may cause augmentation, a phenomenon where symptoms start earlier in the day or spread to other body parts. This limits their chronic use.

Alpha-2-delta calcium channel ligands

• Gabapentin

• Pregabalin

These are preferred in patients with:

• Comorbid pain syndromes

• Peripheral neuropathy

• Insomnia

• Anxiety

Other agents (less commonly used):

• Clonazepam – may improve sleep in refractory cases

• Opioids – reserved for severe, treatment-resistant RLS

? Augmentation: A Unique Challenge

Augmentation is a paradoxical worsening of RLS symptoms over time due to chronic use of dopamine agonists.

Key features:

• Symptoms begin earlier in the day

• Spread to arms or trunk

• Increased intensity or frequency

Management:

• Reduce dose

• Switch to alpha-2-delta ligands or rotigotine patch

• Reassess for contributing factors like low ferritin or poor sleep hygiene

? USMLE Step 2 CK High-Yield Summary

• RLS is a clinical diagnosis with 4 key criteria:

  1. Urge to move the legs

  2. Worsens at rest

  3. Improves with movement

  4. Worse at night

• Always check serum ferritin, even if hemoglobin is normal

• Secondary causes include iron deficiency, pregnancy, CKD, MS, diabetes, and certain medications

• First-line treatment:
  • Dopamine agonists (pramipexole, ropinirole)
  • Gabapentin/pregabalin if comorbid pain or augmentation risk

• Iron supplementation is essential if ferritin <75 ng/mL

• Avoid SSRIs, dopamine blockers, antihistamines, and caffeine/alcohol

? Final Clinical Insight

Restless Leg Syndrome is more than just “fidgety legs” — it’s a sleep disorder that can severely impact quality of life if unrecognized. The key is to listen for the timing, triggers, and relief patterns in the patient’s history.

On exams and in practice, when a patient says they "can’t fall asleep because of a creepy-crawly sensation in their legs that improves with walking," your answer should be:

“That’s RLS – check ferritin and consider a dopamine agonist.”

? Neurosyphilis – Treponema Invading the CNS

? Introduction: What Is Neurosyphilis?

Neurosyphilis refers to central nervous system involvement by Treponema pallidum, the spirochete responsible for syphilis. While it is classically associated with late (tertiary) syphilis, it can in fact occur at any stage, particularly in immunocompromised individuals, such as those with HIV.

It remains a high-yield topic on USMLE Step 2 CK, especially in clinical vignettes involving unexplained neurologic deficits, personality changes, or stroke in a young adult.

Treponema pallidum reaches the CSF via hematogenous spread, and over time causes inflammation, vascular injury, and neural tissue destruction.

? Forms of Neurosyphilis: Clinical Spectrum

Neurosyphilis can manifest in several distinct forms, based on which structures are involved and when the disease presents.

1. Asymptomatic Neurosyphilis

• No neurologic symptoms or signs

• Diagnosed via abnormal CSF findings:
  • Lymphocytic pleocytosis
  • Elevated protein
  • Positive CSF-VDRL

Seen in early stages or as an incidental finding in syphilis follow-up.

2. Meningovascular Neurosyphilis

• Involves inflammation of meninges and blood vessels of the CNS

• Presents with:
  • Headache
  • Cranial nerve palsies
  • Stroke-like symptoms, especially in young adults

• The mechanism is endarteritis obliterans, leading to infarction

MRI may show:

• Multiple small infarcts

• Leptomeningeal enhancement

3. General Paresis (Paretic Neurosyphilis)

• A progressive meningoencephalitis causing neuropsychiatric deterioration

• Presents years after initial infection

• Classic features:
  • Dementia
  • Personality changes
  • Memory loss
  • Mood lability or depression
  • Delusions and hallucinations

This form can mimic psychiatric illness, so always keep it in the differential when evaluating atypical psychosis or cognitive decline, especially in younger adults.

4. Tabes Dorsalis (Late Neurosyphilis)

• Occurs decades after infection

• Involves degeneration of the dorsal columns and dorsal roots

Classic clinical signs include:

• Sensory ataxia – unsteady gait due to loss of proprioception

• Lightning pains – sudden, stabbing pains in limbs or torso

• Impaired vibration and position sense

• Positive Romberg sign

• Bladder dysfunction – from sensory denervation

The hallmark eye finding is the Argyll Robertson pupil:

• Pupils are small and irregular

• Do not react to light, but accommodate to near vision
  ("Prostitute's pupils" — they accommodate but don’t react)

? Diagnosis of Neurosyphilis

Diagnosis begins with serologic testing, but confirmation requires CSF evaluation.

Step 1: Serologic Tests

• Start with non-treponemal tests:
  • RPR (Rapid Plasma Reagin)
  • VDRL (Venereal Disease Research Laboratory test)
  • These detect anticardiolipin antibodies and are used for screening and monitoring treatment response

• Confirm with treponemal-specific tests:
  • FTA-ABS (Fluorescent Treponemal Antibody Absorption)
  • TP-PA (T. pallidum particle agglutination)
  • Remain positive for life, even after treatment

Step 2: CSF Analysis

Indicated in patients with:

• Neurologic symptoms suggestive of neurosyphilis

• Treatment failure or persistent high RPR titers

• HIV-positive patients with neurologic complaints

Key CSF findings:

• Positive CSF VDRL – most specific test (although not very sensitive)

• Lymphocytic pleocytosis – usually mild

• Elevated protein

• Reactive CSF FTA-ABS – highly sensitive but less specific

Imaging:

• MRI brain or spine: helpful in meningovascular syphilis or when ruling out stroke, abscess, or mass lesion

• May show meningeal enhancement, cortical atrophy, or white matter changes

? Treatment

The cornerstone of treatment is high-dose intravenous penicillin G, which penetrates the blood-brain barrier effectively.

First-line therapy:

• Aqueous penicillin G:
  • Dose: 18–24 million units/day IV, divided every 4 hours or as continuous infusion
  • Duration: 10–14 days

This regimen is effective for all forms of neurosyphilis.

For penicillin-allergic patients:

• Desensitization is recommended, especially when CNS involvement is confirmed or suspected

• Alternatives (e.g., ceftriaxone) are less well-studied, and not preferred

⚠️ Jarisch–Herxheimer Reaction

A potential complication of treatment, especially within the first 24 hours of starting antibiotics.

Clinical features:

• Fever, chills, headache, myalgias

• Due to immune response to rapid lysis of spirochetes

Management:

• Supportive: antipyretics, fluids

• Do not stop treatment

? USMLE Step 2 CK High-Yield Summary

• Neurosyphilis = Treponema pallidum in the CNS

• Can occur at any stage, not just tertiary

• HIV-positive patients have higher risk

• Clinical subtypes:
  • Asymptomatic – CSF abnormalities only
  • Meningovascular – strokes, cranial neuropathies
  • General paresis – dementia, mood, psychosis
  • Tabes dorsalis – sensory ataxia, lightning pains, Argyll Robertson pupils

• Diagnosis:
  • Start with RPR/VDRL, confirm with FTA-ABS
  • CSF VDRL is confirmatory
  • MRI may show infarcts or atrophy in meningovascular cases

• Treatment:
  • IV penicillin G, 18–24 million units/day for 10–14 days
  • Desensitize penicillin-allergic patients
  • Watch for Jarisch-Herxheimer reaction — treat supportively

? Final Clinical Insight

Neurosyphilis is the "great imitator", capable of mimicking stroke, psychosis, dementia, or myelopathy. It’s a vital differential in young adults with neurologic or psychiatric symptoms, especially if HIV-positive or with a history of risky sexual behavior.

On your Step 2 CK exam, when you see a patient with stroke-like symptoms, personality change, or sensory ataxia, ask:

"Could this be neurosyphilis?"

If yes, get the RPR, then CSF VDRL, and start IV penicillin G.

? Conus Medullaris Syndrome vs. Cauda Equina Syndrome

A High-Yield Neurological Differentiation

? Introduction: Why This Matters

Conus medullaris syndrome and cauda equina syndrome are two neurological emergencies involving the lower spinal cord. Although they may present with similar symptoms such as back pain, lower extremity weakness, and bladder or bowel dysfunction, they differ significantly in:

• Anatomy

• Clinical presentation

• Urgency of management

Recognizing these differences is high-yield for USMLE Step 2 CK and crucial in emergency settings where rapid intervention can prevent permanent neurological disability.

? Anatomy Refresher

Let’s start with the anatomical landmarks:

Conus Medullaris:

• This is the tapered terminal portion of the spinal cord, ending around the L1–L2 vertebral level

• Contains sacral spinal cord segments (S2–S5)

• Injury here affects both upper and lower motor neurons

Cauda Equina:

• Latin for “horse’s tail,” it consists of the lumbar and sacral nerve roots that continue below the conus

• These are peripheral nerves, not spinal cord

• Injury results in lower motor neuron findings

? Common Causes of Both Syndromes

• Large central herniated disc

• Spinal trauma or fracture

• Spinal stenosis

• Epidural abscess or hematoma

• Spinal tumors (primary or metastatic)

• Postoperative complications

⚠️ Conus Medullaris Syndrome: Clinical Features

Conus medullaris syndrome usually presents with a sudden onset of symptoms due to cord-level damage.

Key features include:

• Bilateral symptoms from the start

• Symmetric lower limb weakness (usually less severe than in cauda equina)

• Early bladder and bowel dysfunction
  • Urinary retention
  • Fecal incontinence

• Saddle anesthesia – loss of sensation over the perineum, inner thighs, and buttocks

• Decreased or absent reflexes in the lower limbs

• May also show UMN signs if the lesion extends upward into the spinal cord

Clinical tip:

• Bladder and bowel involvement is early, and symptoms are symmetric and sudden

⚠️ Cauda Equina Syndrome: Clinical Features

Cauda equina syndrome involves compression of multiple peripheral nerve roots, so symptoms often evolve gradually and are more asymmetric.

Key features include:

• Unilateral or asymmetric radicular pain – sharp, shooting pain down one leg

• Asymmetric leg weakness – affects individual myotomes

• Hyporeflexia or areflexia

• Saddle anesthesia – may be less prominent early on

• Late-onset bladder or bowel dysfunction
  • Retention or overflow incontinence may develop after motor deficits

• Sexual dysfunction – may occur with sacral root involvement

Clinical tip:

• Look for progressive unilateral leg pain followed by bladder symptoms, with patchy sensory loss and asymmetric weakness

? Diagnosis

Both conditions require urgent neuroimaging, as delayed treatment may lead to permanent disability.

First-line diagnostic test:

• MRI of the lumbosacral spine
  • Identifies disc herniation, tumor, hematoma, or abscess
  • Helps determine exact location and nature of compression

Additional considerations:

• CT myelography if MRI is contraindicated

• Bladder scan or post-void residual to assess urinary retention

• Electromyography (EMG) may help later to assess denervation patterns

?️ Management

The key principle: treat both syndromes as surgical emergencies

Step 1: Surgical Decompression

• Should be performed within 24–48 hours

• Goal is to relieve pressure, restore function, and prevent further damage

• In cauda equina syndrome, early decompression improves bladder outcomes

Step 2: High-Dose Corticosteroids

• May be considered in conus medullaris syndrome if cord edema or tumor is suspected

• Controversial in trauma; often used in compressive lesions of inflammatory origin

Step 3: Supportive care and rehabilitation

• Bladder management – intermittent catheterization or indwelling catheter

• Physical therapy – prevent contractures, assist mobility

• Bowel regimen – stool softeners, enemas

• Pain control – neuropathic pain may persist after surgery

? Key Differences at a Glance (Verbal Summary)

Onset:

• Conus medullaris = sudden

• Cauda equina = gradual

Motor symptoms:

• Conus = bilateral, symmetric weakness

• Cauda equina = asymmetric, patchy weakness

Bladder/bowel:

• Conus = early involvement

• Cauda equina = delayed involvement

Reflexes:

• Both = hyporeflexia or areflexia (LMN pattern)

Saddle anesthesia:

• Present in both, but more sharply defined in conus medullaris

? USMLE Step 2 CK High-Yield Summary

• Both syndromes present with back pain, leg weakness, and bladder dysfunction

• MRI spine is the first and most important test

• Conus medullaris:
  • Sudden onset
  • Bilateral, symmetric symptoms
  • Early bladder/bowel loss
  • More likely to have UMN and LMN signs

• Cauda equina:
  • Gradual onset
  • Asymmetric radicular pain
  • LMN signs only
  • Saddle anesthesia + late bladder symptoms

• Emergency decompression surgery is critical in both

• Consider high-dose steroids in tumor-related or inflammatory lesions

? Final Clinical Insight

These syndromes are emergencies masquerading as sciatica or radiculopathy. You must act fast. On your exam and in real life, if a patient reports:

“I can’t feel my inner thighs. I’m weak, and I can’t urinate...”

Your immediate response should be:

“Get an MRI. This could be cauda equina or conus medullaris syndrome.”

Time is spinal cord — the sooner you decompress, the more function you save.

? Cerebrovascular Accident (CVA) – Stroke

A Time-Critical Neurological Emergency

? Introduction: What Is a Stroke?

A stroke, or cerebrovascular accident (CVA), is defined as a sudden-onset neurological deficit due to interruption of cerebral blood flow, leading to brain ischemia or hemorrhage.

Strokes are divided into two major categories:

• Ischemic stroke – accounts for approximately 85% of all strokes

• Hemorrhagic stroke – makes up the remaining 15%

On USMLE Step 2 CK, stroke is a high-yield emergency topic, often presented with sudden focal neurological deficits such as:

• Hemiparesis or hemiplegia

• Facial droop

• Aphasia

• Visual loss

• Sensory deficits

• Vertigo or ataxia (in posterior circulation strokes)

? Etiology: Ischemic vs. Hemorrhagic

Ischemic Stroke – 3 Main Mechanisms:

1. Thrombotic:
   • Due to atherosclerotic plaque rupture and in-situ clot formation
   • Common in large vessels like carotids or small perforating arteries

2. Embolic:
   • Clot travels from another source
   • Most often from the heart (e.g., atrial fibrillation, left atrial thrombus) or carotid artery plaque

3. Hypoperfusion:
   • Caused by systemic hypotension or critical stenosis
   • Often affects watershed areas (border zones between vascular territories)

Hemorrhagic Stroke – 3 Main Causes:

1. Hypertensive hemorrhage:
   • Rupture of deep perforating arteries, often in the basal ganglia, thalamus, pons, or cerebellum

2. Cerebral amyloid angiopathy:
   • Common in the elderly, leads to lobar hemorrhage

3. Vascular malformations or aneurysms:
   • Can cause subarachnoid or intracerebral hemorrhage

⚠️ Clinical Presentation

The hallmark of stroke is abrupt-onset neurologic deficit, usually maximal at onset.

Anterior Circulation (carotid system):

• Middle cerebral artery (MCA) territory:
  • Contralateral hemiparesis and hemisensory loss (face and arm > leg)
  • Aphasia if dominant (usually left) hemisphere
  • Hemineglect if non-dominant (usually right) hemisphere
  • Gaze preference toward side of lesion

• Anterior cerebral artery (ACA) territory:
  • Contralateral leg weakness and sensory loss
  • Urinary incontinence
  • Behavioral or personality changes

Posterior Circulation (vertebrobasilar system):

• Brainstem or cerebellum involvement may present with:
  • Vertigo, diplopia, nystagmus, dysarthria
  • Ataxia, vomiting
  • Crossed signs – ipsilateral cranial nerve palsy with contralateral hemiparesis

• Posterior cerebral artery (PCA) territory:
  • Contralateral homonymous hemianopia
  • Visual hallucinations or cortical blindness
  • Memory impairment

? Diagnosis: Stepwise Approach

Step 1: Immediate Non-Contrast Head CT

• Purpose: Differentiate ischemic vs. hemorrhagic stroke

• In ischemic stroke, CT may initially appear normal but rules out bleed

• In hemorrhagic stroke, CT shows hyperdense area (acute blood)

This step is critical to determine eligibility for thrombolysis.

Step 2: Additional Imaging (As Needed)

• CT Angiography or MR Angiography
  • Identifies large vessel occlusion → potential candidate for thrombectomy

• MRI with diffusion-weighted imaging
  • More sensitive in early ischemia, especially in minor strokes or posterior fossa

Step 3: Laboratory and Cardiac Workup

• ECG – look for atrial fibrillation

• Echocardiogram – evaluate for cardiac source of emboli

• Carotid Doppler ultrasound – check for carotid stenosis

• Glucose, electrolytes, CBC, PT/INR, aPTT

? Acute Management

For Ischemic Stroke:

Thrombolysis (IV alteplase):

• Indicated if:
  • Age ≥18
  • Symptom onset within 4.5 hours
  • No contraindications (e.g., recent surgery, bleeding disorder, active bleed, BP >185/110)

• Dose: Alteplase 0.9 mg/kg (maximum 90 mg), 10% as bolus, rest over 1 hour

Mechanical Thrombectomy:

• Considered for large vessel occlusion (e.g., MCA, ICA)

• Time window up to 24 hours in select patients with favorable imaging

Antiplatelet therapy:

• Aspirin started within 24–48 hours in patients not receiving thrombolysis

• Clopidogrel may be added for short-term dual therapy in minor strokes or high-risk TIA

Anticoagulation:

• Indicated for cardioembolic stroke (e.g., atrial fibrillation)
  • DOACs or warfarin
  • Usually started after 3–14 days based on infarct size

For Hemorrhagic Stroke:

• BP control: Target systolic BP <140–160 mmHg

• Reverse anticoagulation: If on warfarin, give vitamin K + PCC

• Neurosurgical consultation: For hematoma evacuation, especially in:
  • Cerebellar bleeds
  • Herniation syndromes
  • Hydrocephalus (may need ventriculostomy)

• Monitor for complications:
  • Seizures
  • Cerebral edema
  • Herniation

⚙️ Supportive and Secondary Management

In-Hospital Monitoring:

• ICU or stroke unit admission

• Blood pressure management

• Glucose control – avoid both hyper- and hypoglycemia

• Swallow evaluation – prevent aspiration pneumonia

• DVT prophylaxis – with intermittent pneumatic compression or low-dose heparin

Secondary Prevention:

• Statin therapy – high-intensity for all ischemic strokes

• Antihypertensive therapy – usually started after acute phase

• Smoking cessation, diabetes control, weight loss

• Carotid endarterectomy or stenting – in symptomatic patients with ≥70% carotid stenosis

? USMLE Step 2 CK High-Yield Summary

• Sudden focal neurologic deficit = stroke until proven otherwise

• First test: non-contrast head CT

• If ischemic and eligible: IV alteplase within 4.5 hours

• Mechanical thrombectomy up to 24 hours in selected patients

• Antiplatelets (aspirin) for non-thrombolysis patients

• Anticoagulation for cardioembolic stroke (e.g., AFib)

• Statins, antihypertensives, and risk factor modification are essential for long-term prevention

• Hemorrhagic stroke: manage BP, reverse coagulopathy, neurosurgical consultation

? Final Clinical Insight

Time is brain. In stroke medicine, every second matters. The faster you act, the more neurons you save.

On exam day and in practice, if someone presents with sudden speech loss, unilateral weakness, or gaze deviation, don’t wait:

“Call a stroke code. Get a CT head now.”

? Viral Encephalitis

An Acute Neurologic Emergency with Infectious Roots

? Introduction: What Is Viral Encephalitis?

Viral encephalitis refers to inflammation of the brain parenchyma caused by a viral infection. Unlike meningitis, which primarily involves the meninges and typically preserves cognition, encephalitis directly affects the brain tissue, leading to altered mental status, behavioral changes, and focal neurologic signs.

It is a high-yield emergency topic for Step 2 CK, especially in patients presenting with:

• New-onset confusion

• Seizures

• Fever

• Personality or behavioral changes

• Focal signs like aphasia or hemiparesis

? Common Viral Causes

Most important and most tested:

• Herpes Simplex Virus type 1 (HSV-1)
  • Responsible for most sporadic fatal encephalitis in adults
  • Classically involves the temporal lobes

Other causes include:

• Arboviruses
  • Transmitted by mosquitoes or ticks
  • Examples: West Nile virus, Japanese encephalitis, Eastern equine encephalitis

• Enteroviruses
  • Especially coxsackievirus and echovirus in children

• HIV and CMV
  • In immunocompromised patients
  • CMV encephalitis may involve ventriculitis

• Rabies virus
  • After animal bite; often fatal once symptoms begin

⚠️ Clinical Presentation

Patients with viral encephalitis often present acutely and may rapidly deteriorate.

Key symptoms:

• Fever

• Headache

• Confusion or altered mental status

• Agitation, hallucinations, or bizarre behavior

• New-onset seizures

• Focal neurologic deficits
  • Aphasia
  • Hemiparesis
  • Cranial nerve abnormalities

HSV-1 encephalitis specifically may present with:

• Personality changes

• Olfactory hallucinations – due to temporal lobe involvement

• Aphasia – if dominant hemisphere is affected

• Memory deficits

Importantly, meningeal signs (e.g., neck stiffness) are often absent or mild, differentiating encephalitis from meningitis.

? Diagnostic Evaluation

Step 1: Neuroimaging (MRI preferred)

• MRI is the first-line imaging modality

• In HSV encephalitis, look for hyperintense lesions in the temporal lobes, especially on T2-weighted or FLAIR sequences

• CT may be normal early, but is useful to rule out mass effect before LP

Step 2: Lumbar Puncture and CSF Analysis

• Essential to confirm the diagnosis

• CSF findings in viral encephalitis typically show:
  • Lymphocytic pleocytosis
  • Elevated protein
  • Normal glucose (although glucose may be low in CMV or HIV-associated cases)

• Red blood cells (RBCs) may be seen in HSV encephalitis, due to hemorrhagic necrosis

Step 3: CSF PCR Testing

• CSF PCR for HSV is the gold standard for diagnosis
  • Highly sensitive and specific
  • Detects HSV DNA directly in the CSF

• Other PCRs may be ordered based on exposure risk (e.g., West Nile virus, CMV, enterovirus)

Step 4: EEG

• May show periodic lateralized epileptiform discharges (PLEDs) in HSV encephalitis

• Useful if patient presents with seizures or confusion of unclear cause

? Management and Treatment

For suspected HSV encephalitis:

• Start empiric IV acyclovir immediately, before PCR results return
  • Dose: 10 mg/kg IV every 8 hours, adjusted for renal function
  • Continue for 14–21 days

Delaying acyclovir can result in permanent neurologic damage or death.

Additional measures:

• Seizure management – use antiepileptics as needed

• Antipyretics – control fever and reduce metabolic demand

• Intracranial pressure monitoring – especially in deteriorating patients

• ICU care – for airway protection and supportive management

For other viral causes:

• CMV: treat with ganciclovir or foscarnet (in immunocompromised patients)

• West Nile virus, rabies, enterovirus: supportive only
  • No specific antiviral therapy is available for most arboviruses
  • Rabies prevention relies on pre- or post-exposure vaccination

? Prognosis and Sequelae

HSV Encephalitis:

• Without treatment: >70% mortality

• With early treatment: mortality drops to 10–20%

• Many survivors still suffer from:
  • Memory impairment
  • Seizure disorders
  • Behavioral changes

Other viral causes:

• Prognosis varies based on:
  • Virus type
  • Host immune status
  • Speed of diagnosis and treatment

? USMLE Step 2 CK High-Yield Summary

• Altered mental status + fever + new-onset seizures = think encephalitis

• HSV-1 is the most important cause → temporal lobe involvement

• Symptoms include:
  • Confusion, hallucinations, aphasia, focal deficits

• CSF: lymphocytic pleocytosis, ↑ protein, normal glucose

• CSF PCR for HSV = definitive test

• MRI shows temporal lobe hyperintensity

• Start IV acyclovir immediately – don’t wait for test results

• EEG may show sharp waves or epileptiform activity

• Treat CMV with ganciclovir or foscarnet if needed

• Most other viral causes require supportive care only

? Final Clinical Insight

Viral encephalitis, especially HSV, is a condition where time is brain. The earlier you start acyclovir, the better the outcome. On exams and in real life, when a patient presents with confusion, fever, and new-onset seizures—and especially if they have olfactory hallucinations or aphasia—think of HSV encephalitis.

Your reflex answer should be:

“Start IV acyclovir now, then confirm with CSF PCR.”

?️ Optic Neuritis

A Demyelinating Clue to Multiple Sclerosis

? Introduction: What Is Optic Neuritis?

Optic neuritis is an acute inflammatory demyelination of the optic nerve, most often seen in young adults, particularly women between 20 and 40 years of age. It typically presents with monocular vision loss and is strongly associated with multiple sclerosis (MS).

In fact, optic neuritis is often the first clinical manifestation of MS, making it a high-yield neurologic and ophthalmologic topic on USMLE Step 2 CK.

It may also occur as an isolated idiopathic event or as part of other demyelinating syndromes like neuromyelitis optica spectrum disorder (NMOSD) or MOG antibody disease, but MS remains the most commonly tested association.

?‍⚕️ Clinical Presentation

The onset of optic neuritis is typically acute or subacute, developing over hours to a few days.

Key symptoms include:

• Pain with eye movement – the hallmark symptom and an early clue to diagnosis

• Monocular visual loss – often central, described as a central scotoma (a blind spot or blurred area in the center of vision)

• Impaired color vision – especially red desaturation (dyschromatopsia)

• Reduced contrast sensitivity – difficulty distinguishing shades or details

• Uhthoff’s phenomenon – transient worsening of symptoms with heat, exercise, or fever

Many patients describe their vision as “washed out,” “foggy,” or “dim,” and may not even notice the central scotoma until it affects daily tasks like reading or driving.

? Physical Examination Findings

Key exam findings:

• Decreased visual acuity – ranging from mild blurring to severe loss in the affected eye

• Relative Afferent Pupillary Defect (RAPD) – also called the Marcus Gunn pupil
  • Detected via the swinging flashlight test, where the affected pupil paradoxically dilates instead of constricting in response to light
  • Indicates optic nerve dysfunction

• Fundoscopic exam:
  • In most cases, the optic disc appears normal (this is known as retrobulbar neuritis)
  • In about 30% of cases, the disc appears swollen, known as papillitis

? Imaging and Workup

First-line imaging:

• MRI of the brain and orbits with gadolinium contrast

This serves two purposes:

1. Confirms the diagnosis of optic neuritis
   • Shows enhancement of the optic nerve due to inflammation

2. Evaluates for multiple sclerosis
   • Detects white matter lesions, especially periventricular, juxtacortical, and infratentorial
   • Dissemination in space on MRI increases risk of future MS diagnosis

CSF analysis (if MS is suspected):

• May show oligoclonal bands and elevated IgG index, supportive of MS but not specific for optic neuritis alone

Visual evoked potentials (VEPs):

• May show delayed latency, but not routinely required if clinical diagnosis is clear

? Treatment

Although optic neuritis often resolves spontaneously over weeks, treatment can accelerate visual recovery.

First-line therapy:

• High-dose IV corticosteroids, typically methylprednisolone 1 g/day for 3–5 days

Steroids do not alter the final visual outcome, but they help speed up recovery and may delay conversion to clinically definite MS in some cases.

Important notes:

• Oral steroids alone are not recommended for initial treatment due to increased risk of recurrence

• Plasma exchange (PLEX) may be considered in steroid-refractory cases, especially in atypical demyelinating syndromes like NMOSD

? Long-Term Management

After the acute episode, further management depends on whether the patient is diagnosed with multiple sclerosis.

If MRI shows demyelinating lesions, and/or CSF shows oligoclonal bands, the patient is at high risk for MS and should be referred to neurology for:

• Disease-modifying therapy (DMT) initiation:
  • Interferon-beta, glatiramer acetate, or newer agents like fingolimod, ocrelizumab, etc.
  • Aim: prevent future relapses and delay disability progression

• Ongoing neurologic monitoring for MS progression

If the optic neuritis is isolated and idiopathic, no long-term medication may be required, but close follow-up is essential.

?  High-Yield Summary

• Young woman (20–40) with painful monocular vision loss = think optic neuritis

• Pain with eye movement is the hallmark feature

• Other symptoms: central scotoma, red desaturation, Uhthoff’s phenomenon

• Physical exam: RAPD (Marcus Gunn pupil) + normal or swollen optic disc

• Diagnosis: MRI brain and orbits with contrast
  • Look for optic nerve enhancement and MS lesions

• Treat with IV methylprednisolone
  • Oral steroids alone not advised

• Consider disease-modifying therapy if MS is diagnosed or suspected

? Final Clinical Insight

Optic neuritis is more than just “an eye problem”—it is a window into the CNS, often heralding multiple sclerosis in young adults. The key is to recognize the painful, monocular visual loss, order the right imaging, and refer to neurology early.

In clinical practice, when a young patient says:

“My vision suddenly got blurry in one eye and it hurts to move it...”

Your next move is:
“Check visual acuity, test for RAPD, and order an MRI brain and orbits with contrast.”

⚡ Epilepsy

A Foundational Topic in Clinical Neurology

? Introduction: What Is Epilepsy?

Epilepsy is a chronic neurological disorder characterized by a predisposition to recurrent unprovoked seizures. These seizures result from abnormal, excessive, synchronous neuronal activity in the cerebral cortex.

A diagnosis of epilepsy is made when a patient has:

• Two or more unprovoked seizures that occur more than 24 hours apart,

• OR one unprovoked seizure with a high risk of recurrence based on clinical evaluation and EEG findings.

This condition is a high-yield topic on USMLE Step 2 CK, especially when distinguishing seizure types, choosing the correct diagnostic tools, and selecting the appropriate antiepileptic therapy.

? Seizure Classification: Focal vs. Generalized

1. Focal (Partial) Seizures

These arise from a specific focus in one cerebral hemisphere.

• Focal aware seizures (formerly simple partial):
  • Patient remains fully conscious
  • Symptoms may include motor jerks, tingling, or visual changes localized to one body area

• Focal impaired awareness seizures (formerly complex partial):
  • Altered or impaired consciousness
  • Often begin with an aura
  • May feature automatisms (e.g., lip-smacking, hand-rubbing)
  • Frequently arise from the temporal lobe

2. Generalized Seizures

These involve both hemispheres simultaneously and always affect consciousness.

Common subtypes include:

• Tonic-clonic (grand mal) seizures:
  • Begin with tonic stiffening followed by clonic jerking
  • Often associated with a cry, tongue biting, incontinence
  • Followed by postictal confusion and fatigue

• Absence seizures:
  • Classically seen in children
  • Present with brief staring episodes (often unnoticed)
  • No postictal confusion
  • EEG shows 3-Hz spike-and-wave discharges

• Myoclonic seizures:
  • Sudden, brief jerks of limbs or trunk, often upon awakening

• Atonic seizures:
  • Sudden loss of muscle tone, leading to falls (“drop attacks”)

? Clinical Clues for Board Questions

• A child staring in class with sudden brief lapses in attention → Think absence seizure

• A teenager with early morning limb jerks → Think juvenile myoclonic epilepsy

• An adult with strange smells, déjà vu, followed by confusion → Likely focal impaired awareness seizure

• A woman with loss of consciousness, rhythmic jerking, and postictal sleep → Classic tonic-clonic seizure

? Diagnostic Evaluation

Step 1: Thorough Clinical History

• Most critical step

• Ask about:
  • Onset and duration
  • Movements
  • Triggers
  • Postictal symptoms
  • Auras
  • Witness accounts

Step 2: EEG (Electroencephalogram)

• Confirms seizure type

• May show epileptiform discharges, spike-and-wave, or focal sharp waves

• Normal EEG does not rule out epilepsy

Step 3: MRI Brain

• Recommended in all new-onset seizures

• Detects structural causes like:
  • Tumors
  • Cortical dysplasia
  • Mesial temporal sclerosis

Step 4: Rule Out Reversible Causes

Especially in first-time seizures:

• Electrolyte disturbances (e.g., hyponatremia, hypocalcemia)

• Hypoglycemia or hyperglycemia

• Alcohol withdrawal

• Infections (meningitis, encephalitis)

• Medications or toxins

? Treatment Principles

First-time seizure:

• If cause is correctable or provoked, no long-term AED required

• If epilepsy is diagnosed, initiate antiepileptic drug (AED) therapy

Drug selection depends on seizure type:

• Focal seizures:
  • Carbamazepine, phenytoin, lamotrigine, levetiracetam

• Generalized tonic-clonic seizures:
  • Valproic acid, levetiracetam, lamotrigine

• Absence seizures:
  • Ethosuximide (first-line)
  • Valproic acid (if multiple seizure types)

• Myoclonic seizures:
  • Valproic acid, levetiracetam, topiramate

Special considerations:

• Women of childbearing age:
  • Avoid valproic acid due to teratogenicity (neural tube defects)
  • Prefer lamotrigine or levetiracetam

• Elderly:
  • Use AEDs with low drug-drug interaction potential
  • Favor levetiracetam or lamotrigine

• Drug-resistant epilepsy:
  • Defined as failure of two appropriate AEDs
  • Consider surgical resection (e.g., temporal lobectomy)
  • Vagus nerve stimulation (VNS) or responsive neurostimulation (RNS) may be used

? Lifestyle and Counseling

• Driving restrictions:
  • Most states require 6–12 months seizure-free before driving
  • Patients must be counseled on local laws

• Medication adherence:
  • Critical to prevent breakthrough seizures
  • Missed doses are a common cause of recurrence

• Avoid seizure triggers:
  • Sleep deprivation
  • Alcohol
  • Bright flashing lights (in photosensitive epilepsy)

• Ketogenic diet:
  • High-fat, low-carb diet used in children with refractory epilepsy

⚠️ Emergency Consideration: Status Epilepticus

Defined as:

• Seizure lasting >5 minutes, or

• Recurrent seizures without recovery of consciousness

First-line treatment:

1. Benzodiazepine – e.g., lorazepam IV or midazolam IM

2. Followed by AED loading – e.g., fosphenytoin, valproate, or levetiracetam

Early intervention is essential to prevent permanent brain injury.

? USMLE Step 2 CK High-Yield Summary

• Epilepsy = ≥2 unprovoked seizures >24 hours apart

• Seizures classified as focal or generalized

• Absence seizures = 3-Hz spike-wave + no postictal confusion

• Tonic-clonic seizures = stiff + jerking + postictal fatigue

• First-line EEG, MRI, and rule out reversible causes

• AED choice depends on seizure type:
  • Ethosuximide for absence
  • Valproic acid for generalized
  • Carbamazepine/lamotrigine for focal

• Avoid valproate in pregnancy

• Refer for surgery or neurostimulation in drug-resistant epilepsy

? Final Clinical Insight

Epilepsy is a spectrum of disorders — from subtle absence seizures in children to dramatic tonic-clonic seizures in adults. The key to mastering epilepsy is understanding seizure classification, recognizing clinical patterns, and choosing the right AED based on the patient’s age, comorbidities, and seizure type.

In your exam and clinical rotations, when someone presents with:

“Recurrent spells of confusion, unresponsiveness, or shaking…”

You should think:
“Is this epilepsy? What type? Is it focal, generalized, or provoked?”

⚡ Epilepsy

A Foundational Topic in Clinical Neurology

? Introduction: What Is Epilepsy?

Epilepsy is a chronic neurological disorder characterized by a predisposition to recurrent unprovoked seizures. These seizures result from abnormal, excessive, synchronous neuronal activity in the cerebral cortex.

A diagnosis of epilepsy is made when a patient has:

• Two or more unprovoked seizures that occur more than 24 hours apart,

• OR one unprovoked seizure with a high risk of recurrence based on clinical evaluation and EEG findings.

This condition is a high-yield topic on USMLE Step 2 CK, especially when distinguishing seizure types, choosing the correct diagnostic tools, and selecting the appropriate antiepileptic therapy.

? Seizure Classification: Focal vs. Generalized

1. Focal (Partial) Seizures

These arise from a specific focus in one cerebral hemisphere.

• Focal aware seizures (formerly simple partial):
  • Patient remains fully conscious
  • Symptoms may include motor jerks, tingling, or visual changes localized to one body area

• Focal impaired awareness seizures (formerly complex partial):
  • Altered or impaired consciousness
  • Often begin with an aura
  • May feature automatisms (e.g., lip-smacking, hand-rubbing)
  • Frequently arise from the temporal lobe

2. Generalized Seizures

These involve both hemispheres simultaneously and always affect consciousness.

Common subtypes include:

• Tonic-clonic (grand mal) seizures:
  • Begin with tonic stiffening followed by clonic jerking
  • Often associated with a cry, tongue biting, incontinence
  • Followed by postictal confusion and fatigue

• Absence seizures:
  • Classically seen in children
  • Present with brief staring episodes (often unnoticed)
  • No postictal confusion
  • EEG shows 3-Hz spike-and-wave discharges

• Myoclonic seizures:
  • Sudden, brief jerks of limbs or trunk, often upon awakening

• Atonic seizures:
  • Sudden loss of muscle tone, leading to falls (“drop attacks”)

? Clinical Clues for Board Questions

• A child staring in class with sudden brief lapses in attention → Think absence seizure

• A teenager with early morning limb jerks → Think juvenile myoclonic epilepsy

• An adult with strange smells, déjà vu, followed by confusion → Likely focal impaired awareness seizure

• A woman with loss of consciousness, rhythmic jerking, and postictal sleep → Classic tonic-clonic seizure

? Diagnostic Evaluation

Step 1: Thorough Clinical History

• Most critical step

• Ask about:
  • Onset and duration
  • Movements
  • Triggers
  • Postictal symptoms
  • Auras
  • Witness accounts

Step 2: EEG (Electroencephalogram)

• Confirms seizure type

• May show epileptiform discharges, spike-and-wave, or focal sharp waves

• Normal EEG does not rule out epilepsy

Step 3: MRI Brain

• Recommended in all new-onset seizures

• Detects structural causes like:
  • Tumors
  • Cortical dysplasia
  • Mesial temporal sclerosis

Step 4: Rule Out Reversible Causes

Especially in first-time seizures:

• Electrolyte disturbances (e.g., hyponatremia, hypocalcemia)

• Hypoglycemia or hyperglycemia

• Alcohol withdrawal

• Infections (meningitis, encephalitis)

• Medications or toxins

? Treatment Principles

First-time seizure:

• If cause is correctable or provoked, no long-term AED required

• If epilepsy is diagnosed, initiate antiepileptic drug (AED) therapy

Drug selection depends on seizure type:

• Focal seizures:
  • Carbamazepine, phenytoin, lamotrigine, levetiracetam

• Generalized tonic-clonic seizures:
  • Valproic acid, levetiracetam, lamotrigine

• Absence seizures:
  • Ethosuximide (first-line)
  • Valproic acid (if multiple seizure types)

• Myoclonic seizures:
  • Valproic acid, levetiracetam, topiramate

Special considerations:

• Women of childbearing age:
  • Avoid valproic acid due to teratogenicity (neural tube defects)
  • Prefer lamotrigine or levetiracetam

• Elderly:
  • Use AEDs with low drug-drug interaction potential
  • Favor levetiracetam or lamotrigine

• Drug-resistant epilepsy:
  • Defined as failure of two appropriate AEDs
  • Consider surgical resection (e.g., temporal lobectomy)
  • Vagus nerve stimulation (VNS) or responsive neurostimulation (RNS) may be used

? Lifestyle and Counseling

• Driving restrictions:
  • Most states require 6–12 months seizure-free before driving
  • Patients must be counseled on local laws

• Medication adherence:
  • Critical to prevent breakthrough seizures
  • Missed doses are a common cause of recurrence

• Avoid seizure triggers:
  • Sleep deprivation
  • Alcohol
  • Bright flashing lights (in photosensitive epilepsy)

• Ketogenic diet:
  • High-fat, low-carb diet used in children with refractory epilepsy

⚠️ Emergency Consideration: Status Epilepticus

Defined as:

• Seizure lasting >5 minutes, or

• Recurrent seizures without recovery of consciousness

First-line treatment:

1. Benzodiazepine – e.g., lorazepam IV or midazolam IM

2. Followed by AED loading – e.g., fosphenytoin, valproate, or levetiracetam

Early intervention is essential to prevent permanent brain injury.

? USMLE Step 2 CK High-Yield Summary

• Epilepsy = ≥2 unprovoked seizures >24 hours apart

• Seizures classified as focal or generalized

• Absence seizures = 3-Hz spike-wave + no postictal confusion

• Tonic-clonic seizures = stiff + jerking + postictal fatigue

• First-line EEG, MRI, and rule out reversible causes

• AED choice depends on seizure type:
  • Ethosuximide for absence
  • Valproic acid for generalized
  • Carbamazepine/lamotrigine for focal

• Avoid valproate in pregnancy

• Refer for surgery or neurostimulation in drug-resistant epilepsy

? Final Clinical Insight

Epilepsy is a spectrum of disorders — from subtle absence seizures in children to dramatic tonic-clonic seizures in adults. The key to mastering epilepsy is understanding seizure classification, recognizing clinical patterns, and choosing the right AED based on the patient’s age, comorbidities, and seizure type.

In your exam and clinical rotations, when someone presents with:

“Recurrent spells of confusion, unresponsiveness, or shaking…”

You should think:
“Is this epilepsy? What type? Is it focal, generalized, or provoked?”

? Cerebellar Disorders

A Core Concept in Neuroanatomy and Clinical Neurology

? Introduction: What Are Cerebellar Disorders?

The cerebellum is the region of the brain responsible for coordination of voluntary movement, posture, balance, gait stability, and motor learning. Unlike the cerebral cortex, it doesn’t initiate movement—it fine-tunes and calibrates it.

Cerebellar disorders refer to any lesion, disease, or dysfunction of the cerebellum. These conditions are high-yield on USMLE Step 2 CK, especially when interpreting neurologic examination findings like ataxia, tremor, or impaired coordination.

? Key Cerebellar Functions and Clinical Correlates

Lesions in the cerebellum produce ipsilateral motor signs, due to its double-crossed output pathways.

Classic cerebellar signs include:

• Ataxia – uncoordinated movement of limbs or gait

• Dysmetria – inability to control range of motion; overshooting or undershooting a target (“past-pointing”)

• Dysdiadochokinesia – inability to perform rapid alternating movements

• Intention tremor – tremor that worsens during goal-directed movement

• Nystagmus – rhythmic oscillation of the eyes, often horizontal or vertical

• Scanning speech – slow, irregular speech with disrupted rhythm

• Wide-based gait – unsteady and broad stance during walking

? Localization of Cerebellar Lesions

Understanding which part of the cerebellum is affected can help predict the clinical presentation.

Midline (vermis) lesions:

• Affect axial and trunk muscles

• Cause gait ataxia, truncal instability, and difficulty sitting upright

• Common in alcoholic cerebellar degeneration

Lateral hemisphere lesions:

• Affect limb coordination

• Result in appendicular ataxia, dysmetria, intention tremor, and dysdiadochokinesia

⚠️ Common Causes of Cerebellar Dysfunction

1. Stroke

• Most commonly involves the posterior inferior cerebellar artery (PICA) or superior cerebellar artery

• Presents with:
  • Sudden vertigo, vomiting, nystagmus, and inability to walk
  • Dysmetria and limb ataxia if lateral hemisphere is involved
  • May mimic vestibular disorders, but gait disturbance is more profound

2. Cerebellar hemorrhage

• A neurosurgical emergency

• May cause sudden headache, vomiting, coma, or hydrocephalus due to compression of the fourth ventricle and brainstem

3. Alcoholic cerebellar degeneration

• Due to chronic alcohol use, typically affects the anterior vermis

• Classic findings: truncal ataxia, broad-based gait, but intact limb coordination

• Often seen in malnourished patients, especially those with thiamine deficiency

4. Multiple sclerosis

• May cause cerebellar dysfunction in young adults

• Presents with scanning speech, limb ataxia, and nystagmus

• MRI often reveals periventricular white matter lesions

5. Paraneoplastic cerebellar degeneration

• Autoimmune cerebellitis due to remote malignancy (e.g., breast, lung, ovarian cancer)

• Rapid onset of gait instability, vertigo, and ataxia

• Anti-Yo, anti-Hu, or anti-Tr antibodies may be detected

6. Inherited or congenital ataxias

• Friedreich ataxia – autosomal recessive, onset in adolescence; associated with cardiomyopathy and diabetes

• Ataxia-telangiectasia – immunodeficiency, telangiectasias, and increased cancer risk

7. Hypothyroidism

• May cause reversible cerebellar dysfunction

• Look for slow reflexes, weight gain, and fatigue

? Diagnostic Evaluation

Step 1: Neurological Examination

• Check for finger-to-nose dysmetria, heel-to-shin ataxia, rebound phenomenon, and Romberg test

• Gait testing (tandem walking) is very sensitive

Step 2: Neuroimaging

• MRI brain is the best modality for:
  • Identifying cerebellar infarcts, demyelination, tumors, or atrophy

• CT scan is useful in the acute setting, especially to rule out cerebellar hemorrhage

Step 3: Laboratory evaluation

• Consider:
  • Thyroid function tests
  • Vitamin E and B12 levels
  • Autoimmune panel
  • Paraneoplastic antibodies
  • Genetic testing for hereditary ataxias

?️ Management Strategy

Management depends on the underlying cause:

For stroke:

• Follow stroke protocols
  • Thrombolysis or thrombectomy if ischemic
  • BP management, neurosurgical evaluation if hemorrhagic

For cerebellar hemorrhage with brainstem compression:

• Emergency decompressive surgery is indicated
  • Posterior fossa decompression may prevent herniation and death

For alcoholic cerebellar degeneration:

• Thiamine supplementation

• Alcohol cessation

• Nutritional support and rehabilitation

For paraneoplastic cerebellitis:

• Treat underlying malignancy

• Consider immunotherapy (e.g., steroids, IVIG, plasmapheresis)

For MS-related cerebellar disease:

• Disease-modifying therapies (e.g., interferon-beta, ocrelizumab)

• Symptomatic treatments for spasticity or tremor

For inherited ataxias:

• Supportive care with:
  • Physical therapy
  • Occupational therapy
  • Assistive devices

? USMLE Step 2 CK High-Yield Summary

• Cerebellar signs = coordination dysfunction, not weakness or sensory loss

• Ipsilateral symptoms due to double decussation

• Classic features:
  • Ataxia
  • Dysmetria
  • Intention tremor
  • Dysdiadochokinesia
  • Nystagmus
  • Scanning speech

• Midline (vermis) lesions = truncal and gait ataxia

• Lateral hemisphere lesions = limb ataxia and intention tremor

• PICA stroke = vertigo, nystagmus, limb ataxia

• Alcoholic cerebellar degeneration = anterior vermis → truncal instability

• Cerebellar hemorrhage = vomiting + headache + ataxia → emergency surgery

• MRI is preferred for imaging cerebellar lesions

• Treat based on etiology: stroke, tumor, autoimmune, or degenerative

? Final Clinical Insight

Cerebellar disorders are all about precision loss, not power loss. When a patient walks like they’re drunk, but alcohol isn’t the reason, always think cerebellum.

On exam and in real life, if you see:

“Wide-based gait, intention tremor, trouble with finger-to-nose testing…”

Your next steps should be:

“Check imaging for cerebellar stroke or degeneration. Rule out reversible causes. Begin coordination rehab.”

? Parkinsonism

A High-Yield Neurologic Concept with Multiple Causes

? Introduction: What Is Parkinsonism?

Parkinsonism is a clinical syndrome defined by the presence of bradykinesia (slowness of movement) along with at least one of the following:

• Resting tremor

• Muscular rigidity

• Postural instability

The most common cause of parkinsonism is Parkinson’s disease (PD) itself, a progressive neurodegenerative disorder due to dopaminergic neuron degeneration in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum.

However, other conditions can mimic PD, collectively termed secondary parkinsonism. Differentiating between idiopathic PD and its mimics is high-yield for Step 2 CK.

? Pathophysiology of Parkinson’s Disease

In idiopathic PD, the degeneration of neurons in the substantia nigra leads to:

• Loss of dopamine in the nigrostriatal pathway

• Functional imbalance between dopaminergic and cholinergic activity

• Progressive loss of motor coordination and postural control

Histologically, PD is marked by the presence of Lewy bodies—abnormal aggregates of alpha-synuclein protein within neurons.

?‍⚕️ Classic Clinical Features of Parkinson’s Disease

Parkinson’s disease typically affects individuals over age 60, though early-onset forms exist.

Core features include:

• Bradykinesia – the most specific and disabling feature
  • Manifested by slowness in starting or completing voluntary movements
  • Patients describe difficulty with buttoning shirts, writing, or walking

• Resting tremor – classically “pill-rolling” tremor of the hand
  • Typically asymmetric and improves with action

• Rigidity – increased resistance to passive movement
  • Often described as “cogwheel rigidity” due to ratchety catch during motion

• Postural instability – seen in later stages
  • Leads to frequent falls, stooped posture, and shuffling gait

Additional features:

• Masked facies – expressionless or reduced facial animation

• Shuffling gait with reduced arm swing

• Micrographia – handwriting becomes small and cramped

• Hypophonia – low, monotonous speech

• Seborrheic dermatitis – common non-motor finding

• Depression and cognitive decline – may occur in later stages

? Secondary Parkinsonism – Key Differentiators

Parkinsonism can arise from causes other than idiopathic PD. These include:

1. Drug-induced parkinsonism

• Often caused by antipsychotics (e.g., haloperidol), metoclopramide, or reserpine

• Typically symmetric

• Less likely to have resting tremor

• May improve upon discontinuation of the offending agent

2. Vascular parkinsonism

• Due to multiple small infarcts in the basal ganglia

• Presents with lower body parkinsonism – gait difficulty, rigidity

• Tremor is usually absent

• MRI may show ischemic changes

3. Atypical parkinsonian syndromes

• Progressive supranuclear palsy (PSP)
  • Early falls, vertical gaze palsy, axial rigidity

• Multiple system atrophy (MSA)
  • Parkinsonism + autonomic dysfunction (e.g., orthostatic hypotension, urinary incontinence)

• Corticobasal degeneration (CBD)
  • Asymmetric motor symptoms + alien limb phenomenon

4. Repeated head trauma

• Seen in boxers or football players

• Called “pugilistic parkinsonism”

• May coexist with dementia or gait instability

? Diagnosis of Parkinsonism

Diagnosis of Parkinson’s disease is clinical—there are no definitive lab tests.

Key diagnostic points:

• Asymmetric onset of resting tremor and bradykinesia is highly suggestive

• A positive response to levodopa therapy supports idiopathic PD

• MRI brain is typically normal in idiopathic PD, but may help rule out:
  • Vascular lesions
  • Normal pressure hydrocephalus
  • Tumors

DaTscan (dopamine transporter imaging):

• Helps differentiate Parkinson’s disease (reduced uptake) from:
  • Essential tremor
  • Drug-induced parkinsonism (normal uptake)

Used in uncertain or early-stage cases.

? Management of Parkinson’s Disease

Treatment is symptomatic, aimed at improving motor function and quality of life.

First-line therapy:

• Levodopa + Carbidopa
  • Most effective agent
  • Levodopa is converted to dopamine in the CNS
  • Carbidopa inhibits peripheral metabolism, allowing more CNS delivery
  • Long-term use may lead to:

  • Wearing-off

  • Dyskinesias (involuntary choreiform movements)

Other medication classes:

• Dopamine agonists: pramipexole, ropinirole
  • Useful in younger patients
  • Side effects: impulse control disorders, hallucinations

• MAO-B inhibitors: selegiline, rasagiline
  • Mild symptomatic benefit, may delay need for levodopa

• COMT inhibitors: entacapone, tolcapone
  • Extend levodopa duration
  • Must be used with levodopa

• Amantadine
  • Provides modest benefit
  • Useful for levodopa-induced dyskinesias

• Anticholinergics: benztropine
  • Used primarily for tremor in younger patients
  • Avoid in elderly due to cognitive side effects

? Advanced Management: When Medications Are Not Enough

For advanced or medication-refractory PD, options include:

• Deep brain stimulation (DBS)
  • Electrodes implanted in subthalamic nucleus or globus pallidus internus
  • Reduces motor fluctuations and dyskinesias

• Apomorphine infusion or duopa pump
  • Used in severe cases for continuous dopamine delivery

? Supportive and Non-Pharmacologic Management

• Physical therapy – improves gait and reduces fall risk

• Occupational therapy – enhances activities of daily living

• Speech therapy – useful for hypophonia or dysphagia

• Fall precautions – install grab bars, remove tripping hazards

• Psychiatric care – for depression, anxiety, and cognitive decline

? USMLE Step 2 CK High-Yield Summary

• Parkinsonism = bradykinesia + resting tremor, rigidity, or postural instability

• Parkinson’s disease is asymmetric, has a resting tremor, and responds to levodopa

• Drug-induced parkinsonism is symmetric and lacks tremor

• PSP and MSA are atypical parkinsonian syndromes with additional red flags

• Diagnosis is clinical, MRI to rule out secondary causes

• Levodopa/carbidopa = most effective treatment

• Dopamine agonists for younger patients or as add-ons

• DBS for advanced or refractory disease

? Final Clinical Insight

Parkinsonism is not one disease—it’s a syndrome with many faces. Some causes respond beautifully to levodopa, while others don’t. Your challenge is to spot the pattern, rule out mimics, and start the right treatment at the right time.

In your Step 2 CK exam or real-world clinic, when you see:

“A 68-year-old with slow movement, masked face, resting tremor, and a shuffling gait…”

Think:
“Parkinson’s disease – start levodopa, educate on motor side effects, and screen for falls.”

? Cerebral Hemisphere Lesions

A High-Yield Core in Neurologic Clinical Reasoning

? Introduction: Why Cerebral Localization Matters

The cerebral hemispheres are responsible for the highest-order brain functions, including:

• Consciousness

• Voluntary motor control

• Sensory perception

• Language and communication

• Executive function and behavior

• Emotion and memory

Each hemisphere is divided into four lobes—frontal, parietal, temporal, and occipital—each responsible for specific neurologic functions. Understanding how lesions in these regions present clinically is crucial for localization-based diagnosis, which is a high-yield concept tested on USMLE Step 2 CK through stroke syndromes, tumors, trauma, infections, and demyelinating diseases.

? Hemisphere Dominance

In over 90% of right-handed individuals, the left cerebral hemisphere is dominant.

• Left (dominant) hemisphere:
  • Language comprehension and production
  • Logic, arithmetic, reading, and writing
  • Analytical and sequential processing

• Right (non-dominant) hemisphere:
  • Spatial awareness
  • Facial recognition
  • Artistic, musical, and emotional processing
  • Attention to the environment (especially left visual field)

This distinction is essential when evaluating aphasia, neglect, or visual field deficits.

? Frontal Lobe Lesions

The frontal lobe governs personality, behavior, executive function, and contains the primary motor cortex.

Key clinical features of frontal lobe lesions:

• Personality changes: apathy, disinhibition, lack of social awareness

• Primitive reflexes: grasp, rooting, snout reflexes may reappear

• Impaired judgment and problem-solving

• Contralateral hemiparesis (UMN-type) if the precentral gyrus (primary motor cortex) is involved

• Eye deviation toward the side of the lesion if the frontal eye fields are affected

• Broca’s aphasia (if lesion in dominant inferior frontal gyrus):
  • Non-fluent speech, good comprehension, poor repetition
  • Patient is aware of their deficits and may be frustrated

? Parietal Lobe Lesions

The parietal lobe integrates sensory input, spatial orientation, and language function (in the dominant hemisphere).

Dominant hemisphere (usually left):

• Gerstmann syndrome (lesion in angular gyrus):
  • Agraphia – impaired writing
  • Acalculia – impaired math
  • Finger agnosia – inability to identify fingers
  • Left-right disorientation

Non-dominant hemisphere (usually right):

• Hemispatial neglect:
  • Inattention to the left side of space and body
  • Patients ignore or deny that the left side exists

Other findings:

• Contralateral hemisensory loss (especially proprioception and light touch)

• Impaired graphesthesia and stereognosis

? Temporal Lobe Lesions

The temporal lobe is key to language comprehension, memory, and auditory processing.

Dominant temporal lobe (left):

• Wernicke’s aphasia (lesion in superior temporal gyrus):
  • Fluent, nonsensical speech
  • Poor comprehension and repetition
  • Patients often unaware of the deficit (anosognosia)

Non-dominant temporal lobe (right):

• Impaired recognition of music, nonverbal sounds, and facial recognition

• Visual and auditory agnosia

Medial temporal lobe and hippocampus:

• Anterograde amnesia – inability to form new memories

• Lesions may also trigger focal seizures with auras, including:
  • Olfactory hallucinations
  • Déjà vu or jamais vu

? Occipital Lobe Lesions

The occipital lobe houses the primary visual cortex, processing input from the contralateral visual fields.

Key clinical features:

• Contralateral homonymous hemianopia – loss of the same visual field in both eyes

• Macular sparing – central vision may be preserved due to dual blood supply from MCA and PCA

• Visual hallucinations – may occur in visual association cortex lesions

• Cortical blindness – in bilateral occipital damage

• Anton syndrome – denial of blindness despite being cortically blind

? Common Clinical Syndromes to Recognize

1. Broca’s Aphasia (left inferior frontal gyrus)

• Non-fluent speech

• Intact comprehension

• Impaired repetition

• Often with right-sided weakness

2. Wernicke’s Aphasia (left superior temporal gyrus)

• Fluent but nonsensical speech

• Poor comprehension and repetition

• Often with right superior visual field defect

3. Gerstmann Syndrome (left angular gyrus)

• Agraphia

• Acalculia

• Finger agnosia

• Left-right disorientation

4. Hemispatial Neglect (right parietal lobe)

• Ignores left visual field and body

• Draws only the right half of objects

• Denies that deficits exist

5. Homonymous Hemianopia (occipital lobe)

• Visual field loss opposite to the lesion

• Macular sparing suggests occipital stroke

? Causes of Cerebral Hemisphere Lesions

Cerebral hemisphere damage can result from a range of acute and chronic conditions:

• Stroke (ischemic or hemorrhagic)

• Tumors – gliomas, metastases

• Trauma – contusions or intracranial hemorrhage

• Infections – abscess, encephalitis

• Demyelination – multiple sclerosis

• Neurodegeneration – Alzheimer’s, frontotemporal dementia

• Seizure foci – especially temporal lobe epilepsy

? Diagnostic Workup

1. Neuroimaging

• MRI brain is the modality of choice for most lesions

• CT head useful in acute stroke or trauma

2. EEG

• Used for seizure localization, especially in temporal lobe epilepsy

3. Neuropsychological testing

• Helpful in evaluating aphasias, memory impairment, or spatial neglect

4. CSF studies

• Indicated when infection, inflammation, or demyelination is suspected

? Management Overview

Treatment depends on the underlying etiology:

• Stroke: Thrombolysis or thrombectomy if indicated, secondary prevention with antiplatelets, statins, BP control

• Tumors: Surgical resection, radiation, chemotherapy

• Epilepsy: Antiepileptic drugs and surgical evaluation for refractory cases

• Infections: Antibiotics or antivirals depending on organism

• MS: Immunomodulatory therapy

• Rehabilitation: Speech therapy, physical therapy, occupational therapy are critical for all patients with cerebral deficits

? USMLE Step 2 CK High-Yield Summary

• Frontal lobe = behavior, motor control → lesion causes personality changes, UMN signs, eye deviation toward lesion

• Parietal lobe = sensation, spatial awareness → lesion causes neglect (non-dominant) or Gerstmann syndrome (dominant)

• Temporal lobe = memory and comprehension → lesion causes Wernicke’s aphasia, seizures, or memory loss

• Occipital lobe = vision → lesion causes contralateral homonymous hemianopia with macular sparing

• Always correlate deficits to lesion location

• Know classic aphasia patterns, neglect syndromes, and visual field defects

• MRI brain is the best imaging modality

• Management is etiology-specific, but supportive care and rehabilitation are universal

? Final Clinical Insight

The brain is a map, and symptoms are the landmarks. If you can trace the neurologic deficits to a specific lobe and hemisphere, you can unlock the diagnosis.

On USMLE and in clinical practice, when a patient presents with:

“Sudden speech difficulty, right face and arm weakness, and eye deviation to the left...”

Think:

“Left frontal lobe – Broca’s area – MCA stroke.”

? Meningitis – Life-Threatening CNS Infection

? Introduction: What Is Meningitis?

Meningitis refers to inflammation of the meninges, the protective layers surrounding the brain and spinal cord. It is often due to infection—bacterial, viral, fungal, or tuberculous—and presents with acute neurologic symptoms, often evolving within hours to days.

This is a life-threatening emergency, particularly in bacterial meningitis, where delayed treatment can lead to death or permanent neurologic damage. Because of its classic presentation, diagnostic urgency, and treatment protocol, meningitis is a high-yield emergency topic on USMLE Step 2 CK.

? Etiology: Organisms by Age and Risk Group

Knowing the likely pathogens helps guide empiric therapy:

In neonates (age <1 month):

• Group B Streptococcus (Streptococcus agalactiae)

• Escherichia coli

• Listeria monocytogenes

In infants and children:

• Streptococcus pneumoniae

• Neisseria meningitidis

• Haemophilus influenzae type B (now rare due to vaccination)